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Abstract
CK2 PHOSPHORYLATION OF HUMAN PAPILLOMAVIRUS 16 E2 ON SERINE 23
PROMOTES INTERACTION WITH TOPBP1 AND IS CRITICAL FOR E2 PLASMID
RETENTION FUNCTION

By Apurva Tadimari Prabhakar, Ph.D.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2021

Major Director: Iain M Morgan, Ph.D.
Edmund G. Brodie Professor
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Chair, Oral and Craniofacial Molecular Biology
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Human papillomaviruses (HPVs) are the causative agents in most cervical cancers
and have been implicated in a rising number of oropharyngeal cancers. HPV positive
oropharyngeal cancers have increased significantly over the last two decades with no
specific anti-viral therapeutic options for the treatment of HPV diseases. During its
lifecycle, HPV16 encoded E2 protein interacts with host cellular factors to regulate viral
transcription, replication and genome segregation/retention. Our understanding of the
cellular partner proteins that E2 uses to mediate its functions remains incomplete.
xx

Previously, an interaction between E2 and the host protein TopBP1 was identified.
In earlier studies, it was also demonstrated that E2 and TopBP1 co-locate to late telophase
chromatin, and that TopBP1 regulates the interaction of E2 with interphase chromatin,
suggesting that TopBP1 may be the chromatin receptor protein mediating E2 segregation
function.
In this study, we sought a more mechanistic understanding of the E2-TopBP1
interaction. We demonstrate that CK2 phosphorylation of E2 on serine 23 promotes
interaction with TopBP1 in vitro and in vivo, and that E2 is phosphorylated on this residue
during the HPV16 lifecycle. We further investigated the consequences of mutating serine
23 on E2 functions. E2-S23A activates and represses transcription identically to E2-WT
(wild-type), and in transient replication assays, E2-S23A is as efficient as E2-WT.
However, E2-S23A has compromised interaction with mitotic chromatin when compared
with E2-WT. In E2-WT cells, both E2 and TopBP1 levels increase during mitosis when
compared with vector control cells. In E2-S23A cells, neither E2 nor TopBP1 levels
increase during mitosis. We additionally tested whether this difference in E2-S23A levels
during mitosis disrupts E2 plasmid retention function. We developed a novel plasmid
retention assay and demonstrate that E2-S23A is deficient in plasmid retention when
compared with E2-WT. siRNA targeted knockdown of TopBP1 abrogates E2-WT plasmid
retention function.
Introduction of the S23A mutation into the HPV16 genome ensued delayed
immortalization of human foreskin keratinocytes (HFK) and higher episomal viral genome
copy number in resulting established HFK. Furthermore, S23A mutation results in an
xxi

aberrant lifecycle; there is an increase in koilocytes (indicative of a more transformed
keratinocyte), a failure of E2 to be stabilized in differentiating epithelium, and a failure to
amplify the viral genome in the epithelium. Overall, our results reveal that CK2
phosphorylation of E2 on serine 23 promotes interaction with TopBP1, which is critical for
E2 plasmid retention function and in HPV16 immortalization of keratinocytes. Moreover,
we demonstrate that TopBP1 regulation of E2 function is required for an optimum HPV
lifecycle. These results will enhance the molecular understanding of the HPV16 lifecycle
in order to identify potential anti-viral targets against HPV.
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CHAPTER 1
Introduction
1.1 Head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) consist of a diverse group of
squamous epithelial malignancies that occurs in the upper aerodigestive tract (Figure 1)
that includes the nasal cavity and paranasal sinuses, nasopharynx, the hypopharynx, larynx,
and trachea, and the oral cavity and oropharynx (1). The incidence of HNSCC is growing.
Worldwide, it constitutes 10% or more of all cancers and is the fifth leading cause of
cancer, with over 680,000 estimated cases diagnosed annually (2). Further, it accounts for
approximately 4% of all cancers in the United States (3). About twice as many men as
women develop HNSCC and it occurs usually in the age group of 50 years and older (4,
5).
Traditionally, tobacco use and alcohol consumption are considered the two most
important risk factors contributing to the development of HNSCC (6). Over the past
decade, HNSCC has become apparent in a cohort of nonsmokers/ minimal smokers who
are human papillomavirus (HPV) positive (Figure 2). These HPV positive patients tend to
develop oropharyngeal cancers, a subset of HNSCC (7, 8). Studies have suggested that
there is an increase in incidence of oropharyngeal cancers caused by a slow epidemic of
HPV infection (9).
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Figure 1. Schematic illustration of anatomical regions where HNSCC can occur.
HNSCC is classified by its location: it can occur in the oral cavity, nasal cavity and
paranasal sinuses, the upper part of the throat near the nasal cavity (nasopharynx), larynx,
or the lower part of the throat near the larynx (hypopharynx). The majority of the HPV
positive HNSCC are found in the region back of the tongue and throat called the oropharynx. Image was obtained from the CDC website (10).
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Figure 2. Incidence of HPV positive and HPV negative tonsillar HNSCC over years.
Over the past decades, despite reduced smoking rates, cases of HNSCC have increased due
to the rise in HPV positive oropharyngeal cancers. Image obtained from CDC website,
based on the study by Ramqvist et al.,2010 (7).
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1.2 Human papillomaviruses (HPVs)
HPVs are DNA viruses that infect both cutaneous and mucosal epithelium (11). Viral
infections are responsible for causing 15% of all human cancers (12) and HPV accounts
for more than 600,000 new cases of cancer worldwide annually (13). These cancers caused
by HPV in women mainly include cervical cancers, vaginal and vulvar cancers. In men,
HPV infection can cause predominantly ano-genital as well as oropharyngeal cancers (14)
(15) (Figure 3). The high-risk HPV (HR-HPV) genotypes, including HPV 16, 18, 31, are
responsible for causing cancers (16). Whereas the low-risk HPVs, such as HPV 6 and 11,
can cause genital warts (17). Research has shown a strong association between
oropharyngeal cancers and HPV, with 95% of HPV positive cases primarily caused by
HPV16 (18-20).
Compared to HPV negative HNSCC, HPV positive cancers possess distinct
demographic, molecular, and clinical characteristics such as a male predominance, younger
age at the time of diagnosis, lower exposure to the classic risk factors such as smoking,
difference in tumor pathways involved with somatic molecular alterations, and the location
it occurs (21-23). Additionally, it has been reported that HPV positive cancer patients have
a better prognosis than HPV negative patients (24-26). Regardless, currently the treatment
for head and neck cancers are not dependent on HPV status. Many studies have proposed
development of de-escalation protocols to maintain high survival rates and mitigate
treatment-related side effects in HPV positive HNSCC (27). Furthermore, there is a dire
necessity for targeted therapeutics to treat HPV positive cancers.

4

Figure 3. Average annual numbers of HPV-associated cancers based on the
anatomical sites and gender. Cervical cancer among women and oropharyngeal cancers
in men are the most common HPV-associated cancers. Based on data from 2013 to 2017,
about 45,300 new cases of HPV-associated cancers occurred in the United States each year,
including about 25,400 among women, and about 19,900 among men (14).
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1.3 Genome organization of high-risk HPV
HPVs are small, circular, non-enveloped, double-stranded DNA viruses with a genome
approximately eight kilobases in length (28). The genome contains approximately eight
ORFs that are all transcribed from a single DNA strand (Figure 4). The ORF is divided
into three functional parts (Figure 4). The early (E) region encodes proteins (E1, E2, E4–
E7) that are essential for viral replication. Then there is the late (L) region that encodes the
structural proteins (L1–L2), required for virion assembly. Also, it consists of the long
control region (LCR), sometimes also referred to as upstream regulatory region (URR),
essentially a non-coding part which consists of cis-elements that are needed for the
replication and transcription of viral DNA (29) (Figure 4).
The early viral proteins, E1 and E2, together are responsible for initiation of the viral
genome replication. E1 is the solo enzyme that HPV expresses which is an ATP-dependent
helicase, essential for viral DNA replication (30, 31). E1 cannot initiate replication on its
own; it requires E2 to function. E2 is a DNA binding protein that has versatile roles in viral
replication, transcription, and cell cycle regulation among other functions (32). E2 protein,
a DNA-binding protein in its homodimer form, can bind to a 12-bp palindromic sequence
around the AT-rich origin of replication. E2 recruits E1 at the origin of replication via a
protein-protein interaction, to initiate replication (33). The functions of E2 are further
discussed in section 1.7.
E4 is expressed at later stages in HPV lifecycles as E1^E4 fusion proteins (34, 35).
Studies have indicated that this E1^E4 protein has various functions such as its ability to
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arrest cell cycle progression and reorganization of cytokeratin networks, to further facilitate
the exit of the virus from the cell (36).
E5 plays a significant role in cell growth and can impair various cell signal transduction
pathways (37-39). In Bovine papillomavirus (BPV), E5 can cause direct transmembrane
activation of the platelet-derived growth factor (PDGF) β receptor, which can further result
in recruitment and activation of cellular signaling proteins, resulting in mitogenesis (40,
41). HPV16 E5 has been shown to alter cell surface levels or activity of numerous different
receptors, including those involved in cell proliferation, such as epidermal growth factor
receptor (EGFR) (42, 43). E5 protein can further directly modulate the host immune
response, which supports onset and persistence of infection (44, 45). Additionally, it can
aid oncoproteins E6 and E7 in cellular transformation and cancer progression (37, 46).
E6 and E7 are the two main oncogenes of HPV (47,48). HR-HPV E6 protein binds to
and degrades the p53 tumor suppressor (49-51). This is brought about by complexing with
a ubiquitin ligase called E6-associated protein (E6-AP), which causes ubiquitination of p53
leading to p53 degradation and evasion of cellular apoptotic and growth arrest responses
(52). E6 has also shown to target proteins like PDZ, which are implicated in cellular
proliferation, signaling pathways, and in maintaining epithelial integrity, ultimately
promoting cellular transformation (53).
E7 interacts with cellular proteins including p21 and pRb (54) which further causes the
disruption of growth-suppressive pRB-E2F complexes, which can stimulate quiescent cells
into a proliferating state, aiding viral replication to proceed efficiently (51, 55-57).
Additionally, E7 has been shown to cause deregulation of several cell cycle genes that are
7

normally regulated by DREAM (Dimerization partner, RB-like, E2F and MuvB), which is
a transcriptional repressor complex. DREAM complex was demonstrated as another
important tumor suppressor which is disrupted by E7 protein that can play an important
role in HR-HPV induced oncogenic transformation, independent of the pRb and p53 tumor
suppressors (58). E7 disrupts the DREAM complex via competitive binding with p130 (a
Rb family pocket protein), which further drives the cell cycle and cell proliferation (59,
60). Thus, in HR-HPV combination of E6 and E7 expression can ultimately promote cell
immortalization and transformation.
The HPV viral genome is enveloped by an icosahedral capsid which is comprised of
two proteins: L1, the major capsid protein, and L2, the minor capsid protein (61). The
different functions of proteins expressed by high-risk HPV are summarized in Table 1.

8

Figure 4. Schematic representation of the HPV16 genome organization. Full
circular genome of HR-HPV16 displaying its 8 different genes and LCR region, whose
functions are specified. Adapted from D'Abramo et al., 2011 (62).
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Table 1. Proteins expressed by high-risk HPV and their major functions (63)
Protein
E1

Role in the virus lifecycle

E2

ATP-dependent DNA helicase, initiates viral
genome replication.
Genome replication, transcription, segregation.
Regulation of cellular gene expression. Cell cycle
and apoptosis regulation.

E4

Cell cycle arrest, viral genome packaging.

E5

Control of cell growth and differentiation. Immune
modulation, interacts with EGF-receptor.

E6

Major oncoprotein. Degradation of p53. Inhibits
apoptosis and differentiation. Interacts with
numerous host proteins.

E7
L1

Major oncoprotein. Cell cycle control. Binds to
pRB-105.
Major capsid protein

L2

Minor capsid protein. Recruits L1. Virus assembly
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1.4 Genomic status of HPV16 and its significance in HNSCC
The genomic status of HPV and its interaction with the host genome has been wellcharacterized in cervical cancer, but less is known with regards to the physical status of the
viral genome in HPV positive HNSCC. A recent study proposed three main types of
genomic status of HPV in HNSCC (Figure 5) based on head and neck cancer data from
TCGA: an episomal state, an integrated state, and as a virus–human hybrid episomal state
(64).
HPV16 typically exists as an episome where the viral DNA is in a circular form (65).
When integrated, the HPV genome gets inserted into and is maintained in the human
genome. This is a common finding in cervical cancers caused by HR-HPV (66-68). It has
been proposed that during HPV integration, there is a loss of E2 expression which can lead
to deregulated expression of E6 and E7, contributing to carcinogenic progression (69, 70).
This can be a potential biomarker for disease progression. Apart from the viral E6 and E7
expression, it is possible that HPV could drive oncogenesis by modification of the host
genomes at sites of integration. Integration can cause disruption of tumor suppressor genes,
high-level DNA amplifications, and interchromosomal rearrangements (71, 72).
A study of TCGA Whole Genome Sequencing (WGS) data (73) suggested a third type
of HPV16 genomic state, wherein the HPV genome is not integrated into that of the host
genome and the HPV can replicate autonomously from its origin, as an independent viral–
human hybrid episome (64) . This was previously interpreted and characterized as being a
combination of episomal and integrated viral genomes existing within the same tumor and
was considered as the “mixed tumors” (74). But the evidence following analysis of TCGA
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data suggested that the viral genome was in fact episomal and replicates joined to a segment
of human DNA (64). This distinction of which patients truly have integrated tumors is
crucial to identify HNSCC patients who are at increased risk. This further emphasizes the
need to use appropriate techniques for categorizing the genomic status of HPV in head and
neck cancer, which is currently lacking (75).
As mentioned in section 1.2, HPV positive HNSCC patients have higher survival rates
than that of HPV negative HNSCC patients. Recent TCGA data has shown that the HPV
positive HNSCC patients with integrated viral DNA fair clinically worse than those with
tumors containing the virus as an episome (76). Identifying the genomic status in HPV
positive HNSCC can aid as a potential biomarker and can help in development of a deescalation treatment protocol for these patients who have a better prognosis and there are
preliminary studies demonstrating the success of de-escalation in HPV positive HNSCC
patients (77, 78).
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Figure 5. Schematic representation of the proposed three main types of HPV16
genomic status in HNSCC. (A) Integrated, where the HPV genome is inserted and
maintained within the host genome; (B) Episomal, where the genome exists as a
circular DNA; and (C) Episomal viral-human hybrid, in which the integrated HPV
dimer or multimer gets excised along with human DNA and together ligated to form
this hybrid episome. Image adapted from Morgan IM et al.,2017 (75).
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1.5 The HPV lifecycle
The HPV16 lifecycle depends on the differentiation process of the human epithelium
it infects (79-80). The viral lifecycle occurs in four different phases (Figure 6). The first
phase is called establishment. In this phase, the virus gains entry through micro-abrasions
in the epithelium to infect the basal layer cells. After their successful establishment in the
basal cells, the HPV is maintained in an episomal state at a copy number of about 50 to
100 copies per undifferentiated cell. Low level expression of viral early proteins such as
E1, E2, E6 and E7 occurs in this phase, which helps in evasion of the host immune response
to infection (81).
Following this, during the maintenance phase of viral lifecycle, the HPV infected basal
cells undergo differentiation. HPV genomes are small and do not encode polymerases or
other enzymes which are necessary for viral replication (82). HPVs rely on host cell
replication proteins to facilitate viral DNA synthesis (83, 84). As the infected host cells
migrate towards the upper layers, different viral proteins are expressed at high levels, and
viral DNA is amplified. In this amplification phase, the number of copies can range up to
thousands per cell. Subsequently, in the final stage the viral genome gets packed inside a
capsid to form progeny virions. This shed virus can then initiate a new infection (85).
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Figure 6. The HPV lifecycle is dependent on epithelial cell differentiation. HPV infects the basal layer of the stratified
epithelium via microabrasions and HPV genomes are maintained as episomes in the nuclei of infected cells. The viral lifecycle
is closely linked to the differentiation process of host cells. As the infected host cells differentiate and migrate upwards, viral
proteins are expressed and viral DNA gets amplified. The later productive stage of the viral lifecycle occurs in the upper
layers of the epithelium and followed by which the progenitor virions are released. Image adapted from d from Woodman et
al., (85).

1.6 E2 protein
The 43 kDa HPV16 E2 protein binds as a homodimer to a 12-bp palindromic DNA
sequence, ACCGN4CGGT, which is present in multiple copies within the LCR of the viral
genome (86). The E2 protein has three domains: the amino terminal transactivation
domain, which is about 200 amino acids; the carboxyl terminal DNA binding domain,
which is about 100 amino acids; and the third domain called the hinge domain, which forms
a flexible link between the other two domains (Figure 7) (87). The hinge domain has roles
in chromatin binding and protein stability (88-90). The transactivation domain can bind
via its one surface to the viral E1 helicase to initiate replication of HPV genomes (91).
Additionally, it is required for transcriptional regulation, interaction with mitotic
chromosomes, and association with numerous cellular proteins (92-95). The C-terminus of
E2 protein comprises a DNA binding domain which can bind to specific consensus motifs
located primarily in the LCR region of the viral genome (96, 97)
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Figure 7. Schematic of HPV E2 protein with its functional domains. E2 is
approximately 370 amino acids in length. Different functional domains of E2 protein are
indicated. The N-terminal transactivation domain of approximately 200 amino acids is
essential for transcription, replication, and viral DNA segregation. This is connected to the
DNA binding domain via a flexible proline-rich hinge domain. E2 is a homodimer and that
can bind to 12-bp palindromic sequences surrounding the A/T-rich origin of replication
(87).
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1.7 Essential roles of the E2 protein in the HPV16 lifecycle
HPV E2 is a regulatory protein which has several crucial functions during the viral
lifecycle, including initiation of viral DNA replication, transcriptional regulation, and
segregation of the viral genome. In addition, a role for E2 in cell cycle regulation,
apoptosis, and senescence have also been demonstrated (98, 99).

1.7.1

Viral DNA replication initiation

HPV genome replication occurs inside nuclear foci and formation of these foci depends
on the E2 protein as it recruits several viral and host cellular proteins needed to synthesize
viral DNA (100-102). The first step in this replication process is that the early E2 protein
binds the upstream regulatory region via its DNA binding domain (97, 103, 104).
Following this, E2 recruits the helicase protein E1 to the HPV origin via a protein-protein
interaction (Figure 8A) (105-107). E1 protein then forms a di-hexameric complex to
interact with the host proteins including DNA polymerase, pol ϵ, replication protein A
(RPA), and topoisomerase I (topoI) (108-111). This recruitment of cellular replication
factors by E1 is needed to replicate the viral genomes (112, 113). E2 then gets displaced in
an ATP-dependent manner, along with removal of nucleosomes from the origin of
replication which reverses the repression, allowing the enhancer proteins to stimulate DNA
replication (106, 114, 115). Although E1 is the primary replication protein, E2 is required
to initiate replication (33, 116).

18

1.7.2

Transcription
E2 protein can either activate or repress transcription depending on the promoter or

enhancer sequence context and the cellular factors with which it interacts (117, 118). E2
has been shown to activate transcription when E2 sites are present upstream from a
heterologous promoter like the herpes simplex virus 1 (HSV1) thymidine kinase (tk)
promoter (119, 120) . Furthermore, overexpression of E2 can repress transcription from the
viral LCR (121). E2 can also recruit several cellular factors via its transactivation domain
to the viral genomes (Figure 8B), which can further influence viral transcription (122124).
E2 protein regulates host gene transcription to alter cellular functions, promoting
infection and facilitating the HPV lifecycle (125-128). This regulation can happen at
multiple levels by controlling cellular gene expression as well as splicing of cellular
transcripts, which are implicated in cancer and cell motility (125). Additionally, HPV E2
proteins can interact and regulate many cellular proteins involved in host transcriptional
regulation, including SMCX, BRD4, topoisomerase I, BRCA1, chromatin remodeling
components p/CAF, CBP, PARP (poly(ADP-ribose) polymerase 1), p300, Sp1, hSNF5,
NAP1 and Mdm2 (122, 129-133). E2 also regulates immune response associated genes
in keratinocytes, which would aid in persistence of viral infection, that can ultimately lead
to cancer (126, 134).
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1.7.3

Genome segregation

The viral genome is maintained as an episome inside the nuclei of the dividing
epithelial cells. During cell division, the HPV genome segregates into daughter cells, which
occurs by tethering to the host mitotic chromosomes to ensure that the viral DNA is
maintained within the nuclei. E2 is important for this viral genome partitioning (135-137).
Via its DNA binding domain, E2 homodimerizes and binds to 12-bp palindromic sequences
in the viral control region, and simultaneously the E2 amino terminal domain complexes
with host mitotic chromatin (Figure 8C) (138, 139). E2 acts as a bridge between the host
chromosome and viral genome, via protein-protein interactions with cellular receptors on
the host mitotic chromatin apparatus (140-144).
1.8 Importance of viral genome segregation
DNA partition or segregation is the process wherein the genetic material is accurately
moved and positioned between the daughter cells during cell division by the formation of
microtubule spindles, which pull chromosomes to opposite cell poles (145). Episomal viral
genomes are retained in the nucleus of infected keratinocytes and are segregated between
daughter cells during cell division via E2 as a bridge, which tethers viral DNA onto the
mitotic chromosomes (93, 146, 147). This is an important step, and if it fails to occur the
viral genome will not enter the nuclei and will be lost in the cytoplasm leading to loss of
viral genomes from infected cells (Figure 9). So, this tethering and viral genome retention
inside the nuclei is very important for the viral lifecycle (148, 149).
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C.

B.

Figure 8. E2 protein functions are mediated through multiple E2 binding sites in the viral genome. The E2 DNA
binding domain binds to sites located in transcriptional enhancers and in the replication origin. The dimeric DNA binding
domain is linked to an N-terminal transactivation domain by a flexible, hinge region. The transactivation domain is
required for transcriptional regulation (A); cooperative binding to the replication origin with the E1 protein (B);
interaction with mitotic chromosomes (C), and association with numerous cellular proteins. Image adapted from
McBride et al., 2006 (140).

A.
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Figure 9. Illustration depicting HPV genome segregation mediated by E2 protein. During the mitotic phase
of host cell division (A), the viral genomes are segregated between daughter cells (B). This occurs when the viral
genome tethers onto the mitotic chromosomes and this is mediated by E2 protein (C). This is an important step,
and if it fails to occur; the viral genome will not enter the nuclei and will be lost in the cytoplasm (D). Adapted
from the original image obtained from the website of science photo library.

1.9 HPV16 E2 and host cellular protein interactions
E2 interacts with a number of cellular proteins to execute its different roles during the
viral lifecycle. These proteins fall into several categories ranging from transcriptional
regulation, RNA processing, apoptosis, cell cycle regulation, nuclear import, and protein
degradation (150).
1.9.1

Role of Brd4 association with E2

The interaction between E2 and bromodomain-containing protein 4 (Brd4) is the best
characterized E2-host protein interaction. Brd4 is a ubiquitous protein and is a component
of both the transcriptional elongation complex pTEFb, to stimulate RNA polymerase II
transcriptional elongation in general (151), and the Mediator complex (152). It is further
characterized as a chromatin-binding adaptor which can recruit distinct transcriptional
regulators to modulate promoter activity through cell cycle progression (153). Brd4 is also
an essential gene that is crucial for G1 transcription and progression into S phase (154,
155). Brd4 is potentially involved in the transcription of most cellular genes and has been
implicated in many cancers (156). With regards to papillomavirus, Brd4 is involved in
multiple processes critical to the viral lifecycle (157).
Brd4 primarily binds to the transactivation domain of the E2 proteins (148). Brd4
mediates E2’s role in transcription modulation (123, 157-160). Studies which conducted
mutational analysis identified two highly conserved residues in the transactivation domain
of E2; R37 and I73 (159-161) , which were demonstrated to be important for direct
interaction with Brd4 (91, 162). When these residues were mutated, it abolished E2mediated transactivation (163-168). Studies have additionally reported that Brd4 can also
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be involved in E2-mediated transcriptional repression (95, 169-171). Also, it was shown
that when the E2-Brd4 interaction was altered, it affected the ability of HPV16 E2 to
regulate host genome expression and cellular movement (172).
Furthermore, studies have shown the role of E2-Brd4 interaction in the viral replication
process. Although there have been contradictory reports on how Brd4 regulates E2mediated viral genome replication (160, 168, 173-175), which seems to be cell type- and
context-dependent, there is evidence to support that Brd4 has a functional role in viral
replication initiation and that Brd4-E2 interaction is not required for continuing DNA
replication (176).
E2 protein associates with host chromosomes to promote retention and partitioning of
viral genome in dividing cells (177, 178). It was previously demonstrated that just the
attachment of E2 protein to mitotic chromatin is not enough to mediate plasmid retention.
E2 seems to form a complex via dual interactions with cellular proteins and two properties
seem to be required for proper plasmid segregation (179). One property for BPV1 E2 is
transcriptional activation (that is mediated by BRD4), and the other is yet to be known
(further discussed in chapter 4). For BPV1 E2, Brd4 is also shown to be the host mitotic
chromatin receptor of E2 for mediating the viral genome interaction (148, 174, 180).
However, for HR-HPV, the E2 proteins do not co-localize with BRD4 on mitotic
chromatin, indicating that BRD4 may not be the mitotic receptor for HR-HPV E2 proteins
(158, 180, 181).
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1.9.2

E2-TopBP1 interaction

Previous work from the Morgan lab
The Morgan lab aimed at identifying cellular partners that HPV16 E2 could interact
with it to carry out different functions, with an aim to better understand the viral cycle.
TopBP1 was identified as a functional interacting partner for HPV16 E2 (182). Previous
work further demonstrated that TopBP1 interacted with E2 both in vitro and in vivo and
regulate the DNA replication function of E2 (182-186). Additionally, TopBP1 and E2 colocalize on mitotic chromatin and TopBP1 regulates the interaction of E2 with host
chromatin in interphase cells (187).
Structure and cellular functions of TopBP1
The 180 kDa topoisomerase IIβ binding protein 1 (TopBP1) is a key scaffold
protein involved in various aspects of nucleic acid metabolism (188). TopBP1 has a
transcriptional activation domain and two surrounding repressor domains and can regulate
transcription (189). It contains 9 BRCT (BRCA1 carboxyl terminal) domains (Figure 10)
which are hydrophobic pockets, some of which can potentially interact with
phosphorylated motifs in other proteins, to regulate several cellular processes (190, 191).
Interactions

with

cellular

proteins

can

be

mostly

regulated

through

phosphorylation/dephosphorylation via the activity of specific kinases and phosphates
(190, 192-195). TopBP1 is a multifunctional nuclear protein. Via its BRCT domains it
mediates interactions with several cellular proteins that are phosphorylated following cell
signaling events and further is involved in DNA replication, ATR checkpoint activation,
DNA repair, mitosis, and transcriptional regulation, as explained below. TopBP1 is a part
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of the replication complex in mammalian cells and is involved in replication initiation
through its interaction with TICCR/Treslin (196-199). TopBP1 is implicated in DNA
damage checkpoint, as TopBP1 is required for activation of ATR via interaction with
ATRIP (ATR interacting protein), in response to replication stress (200, 201). TopBP1 is
also a substrate for ATM. During the viral lifecycle, both ATM and ATR are activated in
order to promote viral genome replication, therefore TopBP1 can be a vital mediator of the
HPV16 lifecycle (202-206).
TopBP1 also has several roles during mitosis to prevent transmission of DNA
damage (such as DNA double strand breaks and catenated DNA) to G1 daughter cells (207210). During mitosis, TopBP1 forms a complex with MDC1 via CK2 phosphorylation of
MDC1 on the mitotic chromatin, and this helps maintain chromosome stability when DNA
double-strand breaks occur (211). Additionally, CK2 mediated phosphorylation of human
Rad9 promotes the interaction between Rad9-Hus1-Rad1 (9-1-1) and TopBP1 and has an
important role in ATR-dependent checkpoint (212). TopBP1 can directly interact with the
transcription factor E2F1 and control its transcription and apoptotic functions (213).
TopBP1 can regulate p53 target genes by a direct complex formation with p53 protein and
can regulate properties of several mutant p53 proteins that can cause transformation (214).
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Figure 10. TopBP1 BRCT domain structure. TopBP1 can interact with various cellular
and viral phosphorylated proteins though these BRCT domains (190).
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1.10

Purpose of the study

E2 and TopBP1 are nuclear proteins and have overlapping functions including
replication, transcription and chromatin interaction during mitosis (184-187). This
suggested that TopBP1 may be the chromatin receptor protein mediating E2 segregation
function. Previously, a structural mutant of E2 was identified that had a compromised
interaction with TopBP1. This mutant also had a reduced replication function at low levels
of E2 protein (185). In this mutant, asparagine 89 and glutamic acid 90 of E2 were mutated
to tyrosine and valine, respectively (185). However, this is a structural mutant; the
hydrophobic tyrosine and valine residues would potentially repel the interaction with
hydrophobic TopBP1 BRCT domains. Therefore, in this thesis, we aimed at obtaining a
more mechanistic understanding of the E2-TopBP1 interaction.
The hypothesis of this study was that HPV16 E2 mediates the segregation of viral
genomes in host cells using TopBP1 as the mitotic chromatin receptor, which would keep
the viral genome circular inside the nucleus. This study aimed at closing a gap in our
understanding of E2 and host cellular protein interactions, which are needed for viral
lifecycle progression. This could potentially aid in identifying therapeutic targets for the
treatment of cancers caused by HPV16.
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CHAPTER 2
Materials and methods
2.1 Generation of stable cell lines
Stable cell lines expressing wild type E2 (E2-WT), E2-S23A and E2-S23D (the aspartic
acid mimics phosphorylation), along with pcDNA empty vector plasmid control were
established both in U2OS and N/Tert-1 cell lines as previously described (125, 126). Low
passage U2OS cells were seeded at 3 x 105 cells per 100-mm plate in Dulbecco's modified
eagle medium (DMEM) with 10% Fetal Bovine Serum (Invitrogren) and 1% (v/v)
penicillin/streptomycin mixture (Thermo Fisher Scientific) at 37 °C in a 5% CO2/95% air
atmosphere. The next day, the cells were transfected with 1 µg of E2-WT or E2-S23A or
E2-S23D or pcDNA empty vector plasmid DNA containing a G418 resistance gene using
the calcium phosphate method (215). After 48h of transfection, the cells were trypsinized
with 0.5% trypsin EDTA (Invitrogren) and re-plated at 1:10 and 1:50 dilutions in DMEM
media containing G418 (Thermo Fisher Scientific) at a concentration of 0.75 mg/ml.
N/Tert-1 cells were cultured in keratinocyte serum-free medium (K-SFM) (Invitrogen;
catalog no. 37010022) supplemented with bovine pituitary extract, EGF (Invitrogen), 0.3
mM calcium chloride (Sigma; 21115) and 1% (v/v) of penicillin/ streptomycin mixture
(Thermo Fisher Scientific) at 37 °C in a 5% CO2/95% air atmosphere. Stable E2-WT, E2S23A, E2-S23D and pcDNA empty vector containing a G418 resistance gene were
generated utilizing Lipofectamine 2000 (according to the manufacturer’s instructions,
ThermoFisher Scientific). After 48h of transfection, the cells were trypsinized with 0.5%
trypsin EDTA (Invitrogren) and re-plated at 1:10 and 1:50 dilutions in supplemented
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K-SFM media containing G418 (Thermo Fisher Scientific) at a concentration of 0.75
mg/ml G418. Both cell types were closely monitored and re-fed with fresh G418containing media every 3-4 days, for the next 14 days. Following this the cells growing in
isolated colonies were observed which were trypsinized and re-plated onto 100-mm plates
with G418 medium. E2 expression was confirmed using western blot analysis.
2.2 Western blotting
E2 stable cell lines generated above were trypsinized and washed with 1x phosphatebuffered saline (PBS). Protein from the cell pellets was extracted with 2x pellet volume of
protein lysis buffer (0.5% Nonidet P-40, 50mM Tris [pH 7.8], and 150mM NaCl)
supplemented with protease inhibitor (Roche Molecular Biochemicals) and phosphatase
inhibitor cocktail (Sigma). The cells were lyzed for 20 min on ice followed by
centrifugation at 18,000 x g relative centrifugal force (rcf) for 20 min at 4°C to harvest the
lysate. Bio-Rad protein estimation assay was used for protein concentration estimation. 50
µg of protein was combined with equal volume of 4X Laemmli sample buffer (Bio-Rad)
then heat denatured using a heat block at 95oC. The samples were seperated on a Novex™
WedgeWell™ 4 to 12% Tris-glycine gel (Invitrogen) and using the wet-blot method,
transferred onto a nitrocellulose membrane (Bio-Rad) at 30 V overnight. The membrane
was blocked with Li-Cor Odyssey® blocking buffer (PBS) diluted 1:1 with 1x PBS and
then incubated with specified primary antibody in Li-Cor Odyssey® blocking buffer (PBS)
diluted 1:1 with 1x PBS. Following this, the membrane was washed with 1 X PBS
supplemented with 0.1% Tween and further probed with the Odyssey secondary antibodies
(IRDye® 680RD Goat anti-Rabbit IgG (H + L), 0.1 mg or IRDye® 800CW Goat anti30

Mouse IgG (H + L), 0.1 mg) in Li-Cor Odyssey® blocking buffer (PBS) diluted 1:1 with
1x PBS at 1:10,000 for 1 h at room temperature. After washing with PBS-tween, the
membrane was imaged using the Odyssey® CLx Imaging System and ImageJ was used for
quantification. Primary antibodies used for western blotting studies are as follows: HPV16
E2 (TVG 261) at 1:500 dilution (Abcam; ab17185) monoclonal B9 1:500 (Abcam ab17185
for TVG261, (216) for monoclonal B9), TopBP1 at 1:1000 dilution (Bethyl; catalog no.
A300-111A), GAPDH at 1:10,000 dilution (Santa Cruz; catalog no. sc-47724), Casein
kinase IIα (1AD9) at 1:500 dilution (Santa Cruz; catalog no. sc-12738), CKII alpha'
Antibody at 1:1000 dilution (Bethyl; catalog no. A300-199A).
2.3 In vivo immunoprecipitation
Cell lysate was prepared as described above. 250 µg of the lysate was incubated with
lysis buffer (0.5% Nonidet P-40, 50mM Tris [pH 7.8], and 150mM NaCl) supplemented
with protease inhibitor (Roche Molecular Biochemicals) and phosphatase inhibitor cocktail
(Sigma) to a total volume of 500 µl. Primary antibody of interest or a HA-tag antibody
(used as a negative control) was added to this prepared lysate and rotated at 4°C overnight.
The following day, 40 µl of protein A beads per sample (Sigma, equilibrated to lysis buffer
as mentioned in the manufacturer’s protocol) was added to the above mixture and rotated
for another 4 hours at 4°C. The samples were gently washed with 500 µl lysis buffer by
centrifugation at 1000 x g for 2-3 min. This wash was repeated for 4 times. The bead pellet
was resuspended in 4X Laemmli sample buffer (Bio-Rad), heat denatured and centrifuged
at 1000 x g for 2-3 min. The supernatant was gel electrophoresed using an SDS-PAGE
system which was later transferred onto a nitrocellulose membrane using wet-blot transfer
31

method. The membrane was probed for the presence of E2 or TopBP1, as mentioned in the
description of immunoblotting above.
2.4 Immunofluorescence
U2OS cells expressing stable E2-WT, E2-S23A and pcDNA empty vector plasmid
control were plated on acid-washed, poly-L-lysin-coated coverslips in a 6-well plate at a
density of 2 x 105 cells / well (5 ml DMEM + 10% FBS media). After 24 h, the cells were
treated with 2 mM thymidine diluted in the supplemented DMEM media for 16 h. This was
then washed 2 times with 1 X PBS and recovered in supplemented DMEM media. After 8
h, to block the cells at G1/S phase, a second dose of 2 mM thymidine was added and
incubated for 17 h. The cells were then washed twice with 1 X PBS and recovered as before
for 3 h. The cells were next treated with nocodazole (100 ng/ml) for 5 h and released for 2
h to enrich for mitotic cells. Following this, the cells were washed twice with 1 x PBS,
fixed and stained as previously described (176).
The primary antibodies used are as follows: HPV16 E2 (TVG 261) 1:500 (Abcam;
ab17185), HPV16 E2 B9 monoclonal antibody, 1:500 (216), TopBP1 1:1000 (Bethyl;
catalog no. A300-111A), pS23-Ab 1:10,000 (Custom generated by GenScript; peptide
sequence- CKILTHYENDSPTDLR). For lifecycle studies, the antibodies used were as
follows: BrdU, 1:500 (Cell Signaling Technology) and immune complexes were visualized
using Alexa 488- or Alexa 595-labeled antispecies-specific antibody conjugates
(Molecular Probes). The cells were thoroughly washed and incubated with secondary
antibodies Alexa fluor 488 goat anti-mouse (Thermo fisher; catalog no. A-11001) or Alexa
fluor 594 goat anti-rabbit (Thermo fisher; catalog no. A-11037) diluted at 1:1000. The
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wash step was repeated as before, and the coverslips were mounted on a glass slide using
Vectashield mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI). Images
were captured with a Zeiss LSM700 laser scanning confocal microscope and analyzed
using Zen LE software.
2.5 Cell synchronization and FACS analysis
U2OS cells expressing stable E2-WT, E2-S23A and pcDNA empty vector plasmid
control were plated at 3 x 105 density onto 100-mm plates in DMEM + 10% FBS media.
The cells were treated with 2 mM thymidine diluted in the supplemented DMEM media
for 16 h. The cells were then washed 2 times with 1 X PBS and recovered in supplemented
DMEM media. After 8 h, to block the cells at G1/S phase, a second dose of 2 mM
thymidine was added and incubated for 17 h. The cells were then washed twice with 1 X
PBS and recovered as before at different time points as follows: 0 h and 2 h (G1/S phase),
4 h and 6 h (S phase), 8 h (M1 phase), 10 h (M2 phase), and 12 h (the next G1 phase). The
cell lysates were prepared using the harvested cells at different time points and
immunoblotting was carried out as mentioned in the section above. Propidium iodide
staining and FACS analysis with a FACSAria™ fusion SORP high-speed cell sorter
(Becton Dickinson), using FlowJo software was used for the cell cycle phase analysis.
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2.6 Transient transcription activation and repression assays
Parental U2OS cells were plated at a density of 1 x 105 cells per 60 mm plate. Next day,
the cells were transiently transfected with plasmids mentioned below, using calcium
phosphate transfection method. We measured the transcriptional activation potential of E2WT and E2-S23A using our ptk6E2-luc system, a plasmid with 6 E2 sites located upstream
from the HSV-1 tk promoter driving expression of luciferase. Plasmids used for
transcription activation (119, 120): 1 µg ptk6E2-luc + 1 µg E2-WT, 1 µg ptk6E2-luc + 1
µg E2-S23A or 1 µg ptk6E2-luc alone. Plasmids used for transcription repression (217): 1
µg HPV16 LCR-luc + 1 µg E2-WT, 1 µg HPV16 LCR-luc + 1 µg E2-S23A or 1 µg HPV16
LCR-luc alone. pGL3control, containing the SV40 promoter and enhancer driving the
expression of the luciferase gene, was included in each of the experimental setup to confirm
similar levels of transfection efficiency between experiments. 24 h post transfection, cells
were washed with 1 X PBS and re-fed with DMEM media + 10% FBS. After 48 h from
initial transfection, the cells were washed twice with 1 X PBS and further lyzed with 550
µl of 1X reporter lysis buffer (Promega) at room temperature by rocking for 15 min.
Lysates were then harvested by scraping and transferred into 1.5 ml microcentrifuge tubes.
The tubes were then centrifuged at 4°C for 10 min at maximum speed to separate the
supernatants. 80 µl of this supernatants were used for luciferase activity analysis using the
luciferase assay system (Promega). The Bio-Rad protein estimation assay was used for
protein concentration estimation, to standardize for cell number. Relative fluorescence
units were measured using the BioTek Synergy H1 hybrid reader. The activities shown are
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expressed relative to the respective protein concentrations of the samples. The assays
shown are representative of three independent experiments carried out in triplicates.
2.7 Plasmid retention assay
This assay is based upon the well-established fact that transfected DNA is lost from
cells if there is no selective pressure put on them to retain the plasmid DNA; transfected
DNA is quickly located to the cytoplasm and after day three the DNA is quickly lost (218).
Two luciferase reporter plasmids were used for our novel assay; one containing the SV40
promoter and enhancer (pGL3 Control, Promega) which has no E2 DNA binding sites, the
other with the HSV1 tk promoter driving expression of luciferase with 6-E2 target sites
upstream. ptk6E2-luc plasmid has almost no activity in the absence of E2, therefore cannot
be used to monitor for luciferase loss in non-E2 expressing U2OS cells. The pSV40-luc
and the ptk6E2-luc were transiently transfected, separately into either E2-WT or E2-S23A
cells. Three days post-transfection the cells were trypsinized and half re-plated and half
harvested for luciferase assay (Promega). This luciferase activity was considered as the
baseline activity. At day 6, the same process was repeated; half of the cells were harvested
for luciferase assay and half re-plated. At day 9 all the cells were harvested for luciferase
activity assays. The Bio-Rad protein estimation assay was used for protein concentration
estimation, to standardize for cell number. Relative fluorescence units were measured using
the BioTek Synergy H1 hybrid reader. The activities shown are expressed relative to the
respective protein concentrations of the samples. The assays shown are representative of
three independent experiments carried out in triplicates.
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2.8 Small interfering RNA (siRNA) and segregation assay
U2OS parental cells were plated on a 100-mm plates. The next day, cells were
transfected with 10 µM of the following siRNA. Table 2 lists all the siRNAs used in the
study sourced from Sigma-Aldrich. 10 µM of MISSION® siRNA Universal Negative
Control (Sigma-Aldrich; catalog no. SIC001) was used as a “non-targeting” control in
our experiments. The Lipofectamine™ RNAiMAX transfection (Invitrogen; catalog no.
13778-100) protocol was used in the siRNA knockdown. 48 h post transfection, the cells
were harvested, and the knockdown was confirmed by immunoblotting for the protein of
interest. The Segregation assay was performed as described before, after treating the cells
with the siRNA of interest on day 3 of the protocol.

Table 2. List of siRNA used in the study
siRNA name

Target (sense) sequence (5′ to 3′)

TopBP1- A

CUCACCUUAUUGCAGGAGAdTdT

TopBP1- B

GUAAAUAUCUGAAGCUGUAdTdT

TopBP1- C

ACAAAUACAUGGCUGGUUAdTdT

CK2 α

GGCUCGAAUGGGUUCAUCUtt

CK2 α’

CAGUCUGAGGAGCCGCGAGdTdT
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2.9 Production of bacterial recombinant protein
E2-WT and E2-S23D (1-200 aa) were produced as fused proteins with His-tag and
TopBP1 was produced as a fused protein with GST-tag (GST TopBP1 (aa 32- 1522) His
from Addgene; plasmid # 20375). Expression was carried out by picking a single colony
of BL21(DE3) Competent E. coli (NEB Inc.; catalog no. C2527) containing the plasmid of
interest and growing it in LB media supplemented with 100 μg/ml of respective antibiotics
(kanamycin for His-tagged E2-WT and E2-S23D; ampicillin for GST-tagged TopBP1),
grown overnight by shaking at a low speed at 37°C. The starter culture was then diluted
1:100 in fresh LB media with kanamycin, as mentioned above. The culture shaken as
before at 37°C, until the optimal density of 0.6-0.8 at OD600nm was achieved.
Following this, IPTG at final concentration of 1 mM was added to the culture for
induction of protein expression with shaking at 16°C overnight. The His-tagged proteins
were purified on Ni-NTA agarose (Qiagen; catalog no. 30761) and GST-tagged TopBP1
protein was purified on Glutathione Sepharose™ 4B (GE healthcare; catalog no. 17-0756),
according to the batch purification method described in the manufacturer’s manual,
followed by size-exclusion chromatography. The purity of the recombinant protein was
confirmed by SDS–PAGE analysis.
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2.10 In vitro GST pull-down assays
Purified recombinant His-tagged E2-WT and E2- S23D protein and GST-tagged
TopBP1 were used for the In vitro pull-down assays. GST-tagged NEDD4 E3 ligase was
used as our GST-control. GST-TopBP1 and GST-control were kept stable at 0.65 pmol and
11 pmol of His-E2-WT and His-E2-S23D were used for the experiment. GST-TopBP1 and
His-E2-WT or His-E2-S23D were immobilized on Glutathione Sepharose™ 4B (GE
healthcare; catalog no. 17-0756), equilibrated to the GST lysis buffer (50 mM Tris-HCl,
pH 8.0, 100 mM NaCl, 0.5 mM EDTA, 0.5 mM EGTA and 0.5% NP-40, 1 mM DTT plus
protease inhibitors) at 4ºC for 1 h with continual end-to-end rotation.
The protein-bound GST beads were washed 3 times in the GST lysis buffer by
centrifugation at 1000 x g for 3 min and resuspended in 4X Laemmli sample buffer (BioRad), heat denatured and centrifuged at 1000 x g for 2-3 min. The supernatant was gel
electrophoresed using an SDS-PAGE system which was later transferred onto a
nitrocellulose membrane using wet-blot transfer method. The membrane was probed for
the presence of E2 or TopBP1, as mentioned in the description of immunoblotting above.
2.11 In vitro kinase assay with or without lambda phosphatase
Immunoprecipitated GST beads were prepared as mentioned above in the GST-pull
down section. After 1 h incubation, the beads were incubated with 1 µl CK2 enzyme and
1 X CK2 reaction buffer (NEB Inc; catalog no. P6010S) supplemented with 200 µM ATP
and 30 mM MgCl2 and rotated for 1 h at 30ºC. The beads were then incubated in presence
or absence of lambda phosphatase (Santa Cruz; catalog no. sc-200312A) as mentioned in
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the manufacturer’s protocol. Following this, the beads were washed as before and analyzed
by immunoblotting.
2.12 Growth assay
Cells were plated at 1 x 105 per 100-mm plate in their respective growth media. For
siRNA studies, the cells were transfected with the respective siRNAs, the following day of
plating. The cells were grown for 2 days and were trypsinized, then counted. A total of 1 x
105 cells per sample were further plated and allowed to grow for 2 more days. This
procedure repeated for another 2 days. After a total of 6 days, the cells were counted, mean
of the different replicates were calculated, analyzed and plotted on a log scale using
Microsoft Excel.
2.13 CK2 inhibitor treatment
U2OS and N/Tert-1 cells were plated at a density of 2 x 105 in a 100-mm plate. The
next day, the cells were treated with 10 µM CK2 inhibitor, CX-4945 (Silmitasertib) from
APExBIO (catalog no. A8330) or 10 µM DMSO for 48 h. The cells were then harvested
and processed for immunoprecipitation with pS23Ab as described in the section above.
2.14 Organotypic raft culture
N/Tert-1, N/Tert-1 HPV16, N/Tert-1 HPV16-S23A and N/Tert-1 HPV16-S23D cells
were differentiated via organotypic raft culture, as described previously (219, 220). Briefly,
cells were seeded onto type 1 collagen matrices containing J2 3T3 fibroblast feeder cells.
Cells were then grown to confluence on top of the collagen matrices, which were then lifted
onto wire grids and cultured in cell culture dishes at the air-liquid interface, with medium
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replacement on alternate days. Following 13 days of culture, rafted samples were fixed
with formaldehyde (4% [vol/vol]) and embedded in paraffin blocks. Multiple 4 μm sections
were cut from each sample. Sections were stained with hematoxylin and eosin (H&E) and
others were prepared for immunofluorescent staining, as described previously.
2.15 Immortalization of human foreskin keratinocytes (HFK)
HPV16 mutant genomes (S23A and S23D) were generated by Genscript. The HPV16
(WT, S23A, S23D) were removed from their parental plasmid using Sph1, and the viral
genomes isolated and then re-circularized using T4 ligase (NEB) and transfected into early
passage HFK from three donor backgrounds (Lifeline technology), alongside a G418
resistance plasmid, pcDNA. Cells underwent selection in 200 g/mL G418 (SigmaAldrich) for 14 days and were cultured on a layer of J2 3T3 fibroblast feeders (NIH), which
had been pre-treated with 8 g/ml mitomycin C (Roche). Throughout the immortalization
process, HFK were cultured in Dermalife-K complete media (Lifeline Technology). In
Figure 5A, transfected cells were stained with crystal violet 14 days following transfection
and selection prior to passaging.
2.16 Southern blotting
Total cellular DNA was extracted by proteinase K-sodium dodecyl sulfate digestion
followed by a phenol-chloroform extraction method. 5 g of total cellular DNA was
digested with either SphI (to linearize the HPV16 genome) or HindIII (which does not cut
the HPV16 genome). All digests included DpnI to ensure that all input DNA was digested
and not represented as replicating viral DNA. All restriction enzymes were purchased from
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NEB and utilized as per manufacturer’s instructions. Digested DNA was separated by
electrophoresis of a 0.8% agarose gel, transferred to a nitrocellulose membrane, and probed
with radiolabeled (32-P) HPV16 genome. This was then visualized by exposure to film for
1 to 24 hours. Images were captured from an overnight-exposed phosphor screen by GE
Typhoon 9410 and quantified using ImageJ.
2.17 Exonuclease V assay
To examine whether viral genomes were maintained as episomes, we carried out an
exonuclease V assay, as described by Bienkowska-Haba et al. 2018 (221), which
determines the resistance of HPV16 genomes to exonuclease V. 20 ng genomic DNA was
either treated with exonuclease V (RecBCD, NEB), in a total volume of 30 ul, or left
untreated for 1 hour at 37°C followed by heat inactivation at 95°C for 10 minutes. 2 ng of
digested/undigested DNA was then quantified by real time PCR using a 7500 FAST
Applied Biosystems thermocycler with SYBR Green PCR Master Mix (Applied
Biosystems) and 100 nM of each primer in a 20 μl reaction. Nuclease-free water was used
in place of the template for a negative control. The following cycling conditions were used:
50°C for 2 minutes, 95°C for 10 minutes, 40 cycles at 95°C for 15 seconds, and a
dissociation stage of 95°C for 15 seconds, 60°C for 1 minute, 95°C for 15 seconds, and
60°C for 15 seconds. Separate PCR reactions were performed to amplify HPV16 E6 genes.
Table 3 lists the primers used for amplification.
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Table 3. List of primers used in section 2.16
Primer used for the
amplification
HPV16 E6

Sequence
F: 5’- TTGCTTTTCGGGATTTATGC-3’
R: 5’- CAGGACACAGTGGCTTTTGA-3’

HPV16 E2

F: 5’- TGGAAGTGCAGTTTGATGGA-3’
R: 5’- CCGCATGAACTTCCCATACT-3’

Human mitochondrial DNA

F: 5’- AGGAGTAGGAGAGAGGGAGGTAAG3’
R: 5’-TACCCATCATAATCGGAGGCTTTGG -3’
F: 5’- GGAGCGAGATCCCTCCAAAAT-3’
R: 5’- GGCTGTTGTCATACTTCTCATGG-3

Human GAPDH DNA

2.18 Statistical analysis
All the data are represented as means ± SE. Significance was determined using a
student’s t test and standard error was calculated from three independent experiments.
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CHAPTER 3
Results
3.1 E2 serine 23 is critical for TopBP1 interaction in vivo and the E2 S23A mutation
disrupts E2 plasmid retention function.
In a previous study by the Morgan lab, it was demonstrated that TopBP1 and E2 colocalize on mitotic chromatin and that TopBP1 regulates the interaction of E2 with host
chromatin in interphase cells (187). Considering the important role of TopBP1 in regulating
host functions during mitosis (192, 208-210), TopBP1’s ability to regulate E2 interaction
with interphase chromatin, and the co-localization of the two proteins during mitosis (187),
we hypothesized that HPV16 E2 might mediate the segregation of viral genomes in the
host cells using TopBP1 as a hook. Our primary aim in this section was to identify which
residues of E2 mediates the interaction between E2 and TopBP1 and then dissect the
functional aspect this interaction.
3.1.1

S23 is highly conserved in HR-HPV E2 proteins with no known function.

An E2 mutant, N89Y E90V (aspartic acid 89 mutated to tyrosine, glutamic acid 90
mutated to valine), has compromised interaction with TopBP1 (185). This is a structural
mutant where the hydrophobic residues potentially disrupt the interaction with
hydrophobic TopBP1 BRCT domains. Therefore, we set out to gain a more mechanistic
understanding of the E2-TopBP1 interaction. We tested potential phosphorylation sites on
E2 that could mediate TopBP1 interaction, as TopBP1 can bind to a wide variety of
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phosphorylated proteins via its BRCT domains. An E2 protein sequence analysis (Figure
11) showed that serine 23 is highly conserved in alpha-type HPV (which includes highrisk HPVs), without any known function.
3.1.2

E2 interacts with TopBP1 via serine 23.

To explore the interaction between E2 and TopBP1 via serine 23, U2OS cells stably
expressing E2-WT (wildtype), E2-S23A (serine mutated to alanine) and E2-S23D (serine
mutated to aspartic acid, which mimics the negative charge of phosphorylation) were
generated, along with a pcDNA empty vector plasmid control. We used U2OS cells due to
their excellent nuclear architecture for studying mitotic bodies, and it was previously
demonstrated that E2 and TopBP1 co-localize during mitosis in U2OS cells (187). U2OS
cells can also support HPV replication and the maintenance of episomal genomes (222).
The growth rate of the mutants, U2OS E2-S23A and E2-S23D was no different from U2OS
E2-WT (Figure 12). The successful generation of stable cell lines was confirmed by
positive E2 expression, (Figure 13A).
Next, protein extracts from the stable U2OS cell lines (Figure 13A) were
immunoprecipitated using a TopBP1 antibody, and TopBP1 and E2 detected using western
blotting (Figure 13B). E2-WT co-precipitated with TopBP1 (lanes 4, Figure 13B), while
E2-S23A did not (lane 3, Figure). The S23D mutant maintained this interaction (lanes 5,
Figure 13B). This was repeated with three independent extracts and quantitated (Figure
13C).
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3.1.3

E2-WT and E2-S23A have similar transcriptional activation/repression and

replication properties.
Transient E2 transcriptional activation assays demonstrated that both E2-WT and E2S23A are able to repress transcription from a pHPV16-LCR-luc reporter (Figure 14A). E2WT and E2-S23A were also able to activate transcription from ptk6E2-luc reporter with
no significant difference in activity (Figure 14B). Using a transient E1-E2 DNA replication
assay (223), we demonstrated that both E2-WT and E2-S23A were able to activate
replication with no significant difference between them (Figure 14C).
3.1.4

E2-S23A has compromised interaction with mitotic chromatin.

U2OS cells expressing E2-WT, E2-S23A and pCDNA-Vec control were synchronized
to enrich for mitotic cells by double thymidine block. These cells were then fixed and
stained with DAPI, E2 and TopBP1 antibodies. In our pCDNA-Vec control with no E2
expression, TopBP1 did not interact directly with the mitotic chromatin, but a punctate
staining was detected as previously observed (211). E2-WT expressing cells had a strong
interaction with mitotic chromatin, clearly co-localizing with TopBP1 during this process
(Figure 15, middle panels). This was observed repeatedly and demonstrates that E2 recruits
TopBP1 onto mitotic chromatin. E2-S23A had compromised interaction with the mitotic
chromatin. It does co-localize with the chromatin, but the intensity of staining was less
when compared with WT-E2. Although not obvious here, we also observed stronger
TopBP1 staining in many of the E2-WT cells, but never in the E2-S23A cells.
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3.1.5

E2-WT levels are elevated during mitosis, while E2-S23A levels are not.

The results from mitotic staining suggested that E2-WT levels are elevated at mitosis
when compared with E2-S23A. We investigated this by double thymidine blocking of
U2OS pCDNA-Vec, E2-WT and E2-S23A cells, arresting the majority of the cells at G1S transition. The cells were then released and harvested at two-hour time points. Protein
was extracted and used for western blot analysis for TopBP1 and E2 expression (Figure
16). As the cells move into S phase, the protein levels of both E2-WT and E2-S23A
increase (compare the 4-hour time point for both with that of 0 hours). At the 8-hour time
point, we observe a striking difference between E2-WT and E2-S23A. This is when the
cells would complete the S phase following release from the block and enter G2/M. There
was a large increase of E2-WT at this time point but not with that of E2-S23A, where the
E2 levels remained constant. Another striking observation is that with E2-WT, TopBP1
levels are elevated at the 8-hour time point but not with E2-S23A. TopBP1 elevation was
also not observed in pCDNA-Vec control cells. This increase in expression of E2-WT and
TopBP1 at the 8-hour time point was reproducible, as was the clear difference with E2S23A and the results were quantitated as shown in Figure 17. We confirmed the cell cycle
status of these cells at different time points, by flow cytometry. We see that at the 8-hour
time point, most of the cells would be completing S phase following release from the DTB
and entering G2/M (Figure 18). We are currently investigating whether E2-WT is stabilized
during mitosis when compared with E2-S23A.
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3.1.6

E2-WT has a plasmid retention function lost by E2-S23A.

Next, we set out to investigate if the E2-TopBP1 interaction is functionally required for
E2 plasmid retention function and if this is abolished in our E2-S23A mutant. There was
no existing assay to measure E2 plasmid retention function, therefore, we developed an
assay. The principal behind this assay is that, in transiently transfected cells, the transfected
DNA is lost from the cell after 2-3 days unless a selective pressure is placed on the
transfected cell to retain the plasmid (218). Figure 19 summarizes the flow of the plasmid
retention assay. A crucial aspect of our assay is that we are measuring nuclear DNA
because we are measuring transcription. If we followed DNA using PCR, all the DNA that
is in the cytoplasm and which is stuck to the cells and cell culture dish would be detected.
Hence, this luciferase-based assay allows us to monitor nuclear retention of plasmid DNA.
It is also important that the ptk6E2-luc plasmid has almost no activity in the absence of E2,
therefore luciferase cannot be used to monitor for plasmid loss in non-E2 expressing U2OS
cells.
We confirmed that the transcription activity was comparable in both E2-WT and E2S23A as shown in Figure 20. From the results, (Figure 21) we can see that the pSV40-luc
plasmid activity is lost dramatically between day 3 and 6, reduced to almost zero at day 9.
This was irrespective of which E2 protein was expressed. In contrast, ptk6E2-luc activity
was significantly retained by E2-WT between day 3 and day 6 and this retention persists
to day 9, when compared with E2-S23A. The differences between WT-E2 and E2-S23A
were highly significant at days 6 and 9 (please note the log scale on both graphs). This
experiment was repeated three times in triplicate. E2-S23D mutant was not used in these
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assays as the mutant failed to activate transcription. We are currently probing the reasons
for this.
3.1.7

E2-WT loses its ability to segregate after TopBP1 knockdown.

To further investigate the role of TopBP1 in E2 plasmid retention function, we used
siRNA against TopBP1 at day 3 following transfection in our assay. We confirmed
TopBP1 knockdown which persists till day 9 (Figure 22). We also confirmed that siRNA
knockdown of TopBP1 did not affect the growth rate in our E2 cell lines (Figure 23).
TopBP1 knockdown had no effect on pSV40-luc activity. But we see that E2-WT loses its
ability to retain the ptk6E2 plasmid following TopBP1 knockdown (Figure 24). Using two
additional siRNA against TopBP1, we were able to demonstrate the same results (Figure
25). Non-specific scrambled control siRNA (Scr) was used as a control for siRNA
treatment. We were thus able to show that an E2-TopBP1 complex is required for E2-WT
plasmid retention function.
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A.

B.

Figure 11. Motif analysis of the E2 serine 23 residue region. E2 protein sequence
analysis indicated serine 23 to be highly conserved in most α-HPV (A) and high-risk (HR)
HPVs, which are linked to causing cancer (B). The analysis was done by Dr. Renfeng Li.

49

Figure 12. The growth rates of the indicated cell lines. A growth curve was carried out
over 9 days and the accumulated number of cells is plotted on a log graph. The standard
errors are so low and hence do not show on this log-scale graph. Cell numbers were not
statistically significant at any point.
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A.

B.

C.

Figure 13. A system to study E2 –TopBP1 interaction. (A) Western blot showing the
expression levels of indicated proteins in stable U2OS E2 cells. (B) Protein extracts were
immunoprecipitated with HA (control) or TopBP1 antibodies followed by western blotting
for TopBP1 or E2. (C) The experiment described for panel (B) was repeated and the results
were quantitated. * indicates a significant decrease in E2-S3A interaction with TopBP1
when compared with E2-WT, p-value < 0.05. Significance was determined using a
student’s t test and standard error was calculated from three independent experiments.
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Figure 14. Transcriptional activation/repression
and
replication properties of E2-WT

and E2-S23A. U2OS cells were transiently transfected with the indicated plasmids (no E2
indicates pcDNA-Vec control used to maintain identical DNA concentrations in all
samples), and luciferase assays carried out on cell extracts from the transfected cells at day
3 post transfection. The luciferase activity was standardized to protein levels in the cell
extract. Difference in activation (A) or repression properties (B) of E2-WT or E2-S23A,
were not statistically significant. (C) E1-E2-mediated DNA replication assays were carried
out in C33a after transiently transfection with the indicated plasmid. Low-molecularweight DNA was harvested from the transfected cells after 48 hours and replication levels
determined as described (223). There is no replication with E1 alone, E2 and E1 are
required for replication in this assay. There was no statistically significant difference
between the replication levels of E2-WT or E2-S23A. The figure represents a summary of
three independent experiments carried out in duplicate. Replication assay was performed
by Dr. Molly Bristol.
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1g E2-S2

Figure 15. Representative immunofluorescence images depicting the mitotic staining
for E2 and TopBP1. Mitotically enriched U2OS pCDNA-Vec (top panels), E2-WT
(middle panels) and E2-S23A (bottom panels) were stained with DAPI, E2 and TopBP1.
A merge of the two antibodies with DAPI staining is shown in the right-hand panels. The
experiment was repeated multiple times and a similar phenotype was observed.
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Figure 16. Cell synchronization and western blot analysis on U2OS E2 cell lines. U2OS
lines as indicated, were double thymidine blocked to coordinate them in G1. The cells were
then released for the time points shown, and protein extracts harvested and western blots
carried out.
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Figure 17. Quantitation of replicate experiments shown in Figure 16. The top panels
show the levels of E2 relative to GAPDH at various times following release from double
thymidine block, while the bottom panels show the levels of TopBP1 relative to GAPDH
following release. * indicates a significant difference in protein levels between the 0- and
8-hour time points. Significance was determined using a student’s t test and standard error
was calculated from three independent experiments.
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Figure 18. Flow cytometry data for U2OS pCDNA-Vec, E2-WT and E2-S23A. The
cells were double thymidine blocked (DTB) as described in the Materials and Methods.
Following release from the DTB, cells were harvested for flow cytometry analysis.
Propidium iodide staining and flow cytometry analysis with a FACSAria™ fusion SORP
high-speed cell sorter (Becton Dickinson), using FlowJo software, was used for the cell
cycle phase analysis. The plot in the middle panel is a representation of enrichment for
cells in mitosis which was seen in all cell lines, at 8-hour time point.
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Figure 19. Assay to study plasmid retention. Summary of our novel plasmid retention
assay, see section 2.7 for details.
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Figure 20. Quantitation of transcriptional activation by E2-WT and E2-S23A at day
3 of plasmid retention assay. Indicated stable U2OS cells were transiently transfected
with 1µg ptk6E2 and the transcriptional activity at day 3 was measured and quantitated
based on luciferase expression.
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Figure 21. Quantitation of results from plasmid retention assay in U2OS cells. Graph
depicting the luciferase expression of ptk6E2-luc (top panel) and of pSV40-luc (bottom
panel) in E2-WT and E2-S23A cells. The experiment was repeated three times in duplicate.
* indicates a significant difference between the E2-WT and E2-S23A luciferase activity at
the day 6 and 9 time points, p-value < 0.05.
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Figure 22. Western blot analysis to confirm siRNA knockdown of TopBP1 throughout
the plasmid retention assay. The U2OS cells were treated with the indicated siRNAs. The
lysates were probed in western blots using E2, TopBP1 or GAPDH antibodies.
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Figure 23. The growth rates of the indicated cell lines following siRNA knockdown of
TopBP1. A growth curve was carried out over 12 days after addition of siRNA at day 3
and the accumulated number of cells is plotted on a log graph. Cell numbers were not
statistically different at any time point.
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Figure 24. Quantitation of results from plasmid retention assay in U2OS cells followed
by siRNA knockdown of TopBP1. This is a summary of three independent experiments
carried out in duplicate. * indicates a significant difference in the luciferase activity at the
day 6 and 9 time points between the Scr treated E2-WT and other indicated siRNA treated
cell lines, p-value < 0.05.
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by knockdown of TopBP1 with two additional siRNA. We repeated our previously
described plasmid
retention
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9 assay with two additional TopBP1 siRNAs. These experiments
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out once in triplicate. * indicates a significant difference between E2-WT and
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after transfection
all other conditions at the day 6 and 9 time points, p-value < 0.05.

63

E2-S23A + Scr siRN

E2-WT + TopBP1 si

E2-WT + TopBP1 siRNA

*

0.01

0.0001

3

E2-WT + TopBP1 s

siRNA added

9
Activity relative to Day 3 = 1

0.1

E2-S23A + Scr siRN

E2-S23A + TopBP1

0.1

E2-WT + Scr siRNA

Activity relative to Day 3 = 1

Activity relative to Day 3 = 1

1

E2-WT + Scr siRNA

ptk6E2-luc

0.01

0.01

Activity relative to Day 3 = 1

c

siRNA TopBP1 - B

B

3.1 Summary
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Figure 26. A summary of section 3.1. We developed a system to demonstrate that E2
serine 23 is critical for TopBP1 interaction in vivo.

As explained in chapter 1, the E2 viral protein is a central regulator of the HPV lifecycle
through its association with other viral and cellular factors. The Morgan lab previously
demonstrated an E2-TopBP1 interaction (182) that contributes to E2 replication function
and interaction of E2 with interphase chromatin (182-186). In this section, we demonstrate
that E2 serine 23 is critical for TopBP1 interaction in vivo, that E2-S23A mutation
abolished the interaction between E2 and TopBP1 and that S23D maintained this
interaction. We further explored the effect of mutating this serine 23 on E2 functions. The
mutant E2-S23A activates and represses transcription similarly to E2-WT. Further, E2S23A and E2-WT cells have identical replication as shown by transient replication assay.
On the other hand, E2-S23A has compromised interaction with mitotic chromatin when
compared with E2-WT. Both E2 and TopBP1 levels increase during mitosis in E2-WT
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cells, which was not observed in E2-S23A cells. Using our novel plasmid retention assay,
we demonstrated that E2-S23A is deficient in plasmid retention when compared with E2WT. siRNA targeted knockdown of TopBP1 abolishes E2-WT plasmid retention function.
Our next aim was to demonstrate if phosphorylation of S23 promotes the formation of the
E2-TopBP1 complex.
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3.2 CK2 phosphorylation of E2 promotes interaction with TopBP1 in vitro and in vivo.
The data in section 3.1 suggest that phosphorylation of E2 on S23 promotes the
interaction with TopBP1 as the E2-S23D mutant (the acidic charge on aspartic acid, D
mimicking phosphorylation) binds to TopBP1 while S23A does not. Hence, we
investigated if CK2 mediates this phosphorylation. Casein Kinase 2 (CK2) is a ubiquitous
kinase. The enzyme exists as a tetramer composed of two catalytic α-subunits (α, α′) and
two β regulatory subunits. CK2 has been implicated in a lot of cellular processes such as
cell cycle control, cell proliferation, cell growth and survival, promoting angiogenesis, and
is involved in DNA repair (224). Additionally, CK2 is active during mitosis (225), CK2
can interact with E2 (226) , and CK2 phosphorylation promotes interaction of several other
proteins with TopBP1 (226-229).Thus, we investigated whether CK2 phosphorylation on
E2 S23 promotes complex formation with TopBP1.
3.2.1

Recombinant E2-S23D forms a direct complex with TopBP1, in vitro.

Recombinant GST-TopBP1 (full-length), His-E2-WT and His-E2-S23D (amino acids
1-200 for both E2 proteins) were purified from E. coli (Figure 27). These proteins were
incubated together, and a GST pull-down experiment performed, followed by western
blotting (Figure 28A). Lanes 5 and 6 in Figure 28A demonstrate equal levels of E2-S23D
and E2-WT input used in the experiment. An interaction between E2-S23D and GSTTopBP1 is seen in lane 1, while it is evident in lane 2 that E2-WT does not interact with
TopBP1. Neither protein interacts with the GST-NEDD4 control protein. This experiment
was repeated and the results were quantitated (Figure 28B).
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3.2.2

CK2 mediates the interaction between recombinant E2-WT and TopBP1, in

vitro.
Next, to determine whether CK2 phosphorylation of E2-WT can promote interaction
with TopBP1, we incubated the recombinant proteins with CK2 enzyme prior to GST pulldown (Figure 29A). In the presence of an enzymatically active CK2, there is an interaction
between E2-WT and TopBP1 (lane 1, Figure 29A). By excluding the CK2 co-factors
(MgCl2/ATP) (lane 2) or CK2 enzyme (lane 3, Figure 29A), this interaction is eliminated.
CK2 did not promote interaction with the GST-NEDD4 control protein (lanes 5-7, Figure
29A). This experiment was repeated and the results quantitated (Figure 29B).
To confirm whether CK2 phosphorylation promotes the interaction between E2-WT
and TopBP1, we repeated the experiment as described in Figure 29, additionally in the
presence of lambda phosphatase which eliminated the interaction between E2 and TopBP1
(lane 2, Figure 30A). This experiment was repeated and the results quantitated (Figure
30B). This strongly suggests that phosphorylation of E2-WT by CK2 promotes complex
formation with TopBP1 in vitro.
3.2.3

CK2 promotes interaction with TopBP1 in vivo.

To demonstrate if the knockdown of CK2 components, CK2 α or α’ disrupted the E2TopBP1 interaction in vivo, we carried out TopBP1 co-IPs following CK2 α or α’ siRNA
knockdown. Figure 31A demonstrates a successful knockdown of CK2α and a reduction
in the interaction of E2-WT with TopBP1 in these cells (Lane 2, Figure 31B). The HA
control antibody IP does not immunoprecipitate TopBP1 or E2 (Lane 1 and 4, Figure 31B).
We also observe higher E2 protein in the absence of CK2α (lane 2, Figure 31A) and this
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was seen repeatedly, making the reduction in E2-TopBP1 complex formation more
significant. These experiments were reproduced at least three times and quantitation of the
E2 co-IP with TopBP1 demonstrates a significant reduction of complex formation after
CK2α siRNA knockdown (Figure 32). Knockdown of only one CK2 subunit would not
negate the CK2 function completely, as there could be an impact from the CK2α’ subunit.
For this, we repeated the same experiment as above after CK2α’ knockdown and observe
the same phenotype as above (Figure 33 and 34).
The E2-S23D interaction with TopBP1 was not affected by CK2 knockdown. Further,
knock down of CK2α (Figure 31) or CK2α’ (Figure 33) did not affect the protein levels of
E2-S23D, as we see with E2-WT. The results from independent experiments were
quantitated (Figure 32 and 34).
3.2.4

siRNA knock down of CK2 diminishes E2-WT retention of ptk6E2 plasmid.

Next, we investigated the ability of CK2 knock down to disrupt E2-WT plasmid
retention function using our novel assay (Figure 35). We see a sharp reduction in retention
of luciferase activity (day 6), but at day 9 there is only a partial loss of activity when
compared with the E2-S23A mutant activity. This is probably due to a compensatory
mechanism to restore CK2 activity in cells by the other CK2 component when one of them
is knockdown. We also confirmed the knock down of CK2 α or α’ by western blot with the
lysate we used for our retention assay, which remained reduced till day 9 of the assay.
(Figure 36). Knock out of both CK2 α and α’ component was not successful as the cells
were not able to grow out.
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3.2.5

CK2 phosphorylates E2 on serine 23 in vivo, and CK2 inhibitors disrupt the

E2-TopBP1 complex.
A rabbit antibody specific for phosphorylated serine 23 (pS23-Ab) was generated using
a phospho-peptide with the region around S23, wherein the serine is phosphorylated
(CKILTHYENDSPTDLR). We used this antibody to investigate if E2 S23 is
phosphorylated in vivo by CK2. To meet this objective, we knocked down CK2
components using siRNA as shown in Figure 37. CK2 α and α’ expression was downregulated, individually (lanes 2 and 3, respectively Figure 37) and combined (lane 4, Figure
37), following the siRNA knockdown in U2OS pCDNA-Vec and E2-WT. A non-specific
scrambled control siRNA (Scr) was used as a control for siRNA treatment (lanes 1 and 5
respectively Figure 37). We observed a partial knockdown of CK2 α and α’, after co-knock
down of both CK2α components which might be a compensatory mechanism the cells use
for their continued survival. Immunoprecipitation with pS23-Ab in the U2OS pCDNA-Vec
and E2-WT after siRNA knockdown, there was loss of detectable E2 coimmunoprecipitation (co-IP) with the pS23-Ab (lanes 2-4, lower panel Figure 37), whereas
in the Scr treated U2OS E2-WT cells, we see a clear co-IP of E2 (lane 5, lower panel Figure
37).
Subsequently, we used a CK2 inhibitor, CX4945 which is currently a drug used in
clinical trials for a number of human cancers (230). Following treatment with CX4945 in
U2OS E2-WT, the interaction between E2 and TopBP1 was disrupted, and pS23-Ab failed
to co-IP E2 (lanes 3-4, Figure 38).
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3.2.6

E2 is phosphorylated on serine 23 during mitosis.

Figure 39 reveals that in mitotically enriched U2OS E2-WT and E2-S23A cells, pS23Ab antibody recognizes E2-WT, but not E2 S23A, both in mitotic and interphase cells. In
the E2-WT mitotic and interphase cells following pS23-Ab staining, we observed a strong
signal. Whereas with E2-S23A cells, a very marginal signal in mitotic cells and no visible
staining in interphase cells is seen after pS23-Ab staining (see arrow pointed, Figure 39).
We previously confirmed that the E2-S23A protein is detectable after staining with a nonphospho specific E2 antibody in our immunofluorescence result (Figure 15) and that there
is comparable expression of E2-WT and E2-S23A in U2OS cells (Figure 15).
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A.

B.

C.

Figure 27. Western blot analysis to confirm and demonstrate purity of recombinant
proteins. (A) and (B) Recombinant His-E2-WT and His-E2-S23D (amino acids 1-200 for
both E2 proteins) was purified as explained in section 2.9, on a Ni-NTA agarose followed
by size-exclusion chromatography. The expression of respective proteins was confirmed
by western blot analysis (Green fluorescent bands). (C) Recombinant TopBP1 was
produced as a fused protein with a GST-tag (GST TopBP1 (aa 32- 1522) His and purified
on Glutathione Sepharose™ 4B as explained in section. The expression of respective
proteins was confirmed by western blot analysis.
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Figure 28. GST pull-down assay followed by western blot analysis using recombinant
proteins. (A) 11 pmol of E2 was incubated with 0.65 pmol of GST-TopBP1 or GSTNEDD4 at 40C for one hour with rotation. GST pull-downs followed by western blotting
for TopBP1 (top panel) and E2 (bottom panel) were then carried out. Recombinant E2
proteins only were added as input and the TopBP1 pull down demonstrates equivalent
levels of TopBP1 in each condition incubated with TopBP1. (B) Quantitation of repeat
experiments. The binding of E2 to TopBP1 is repressed relative to the E2 input protein
equaling 1. * indicates a significant difference between the two samples under the bracket,
p-value < 0.05. Significance was determined using a student’s t test and standard error was
calculated from three independent experiments.
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Figure 29. GST pull-down assay followed by western blot analysis using recombinant
proteins with CK2 enzyme. (A) The GST pull down was repeated as in Figure 28
following 1 hour at 300C with CK2 and controls. (B) Quantitation of repeat experiments.
The binding of E2 to TopBP1 is expressed relative to the E2 input protein equaling 1. *
indicates a significant difference between the two samples under the bracket, p-value <
0.05. Significance was determined using a student’s t test and standard error was calculated
from three independent experiments.
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A.

B.

Figure 30. Western blot analysis to demonstrate loss of CK2 mediated E2-WTTopBP1 interaction in the presence of lambda phosphatase after GST pull-down. (A)
Lambda phosphatase was added to the CK2 reaction and GST pull-down assays as
mentioned in Figure 28. (B) Quantitation of repeat experiments. The binding of E2 to
TopBP1 is expressed relative to the E2 input protein equaling 1. * indicates a significant
difference between the two samples under the bracket, p-value < 0.05. Significance was
determined using a student’s t test and standard error was calculated from three
independent experiments.
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A.

C.

B.

D.

Figure 31. Western blot analysis to demonstrate CK2α knockdown disrupts E2TopBP1 interaction. Input blots of extracts from indicated siRNA treated U2OS E2-WT
cells (A) and E2-S23D cells (B). TopBP1 co-IP of E2-WT (C) and TopBP1 co-IP E2-S23D
(D) were carried out following CK2α knockdown.
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Figure 32. Quantitation of repeat experiments from Figure 31. The co-IPs of E2 with
TopBP1 in the presence of Scr and CK2α siRNA were quantitated relative to the input
protein levels. The Scr co-IP levels were set as 1. * indicates a significant difference
between the two samples under the bracket, p-value < 0.05. Significance was determined
using a student’s t test and standard error was calculated from three independent
experiments.
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A.

B.

Figure 33. Western blot analysis to demonstrate CK2α’ knockdown disrupts E2TopBP1 interaction. (A) Input blots of extracts from indicated siRNA-treated U2OS Vec,
E2-WT and E2-S23D cells. (B) TopBP1 co-IP of E2-WT or TopBP1 co-IP E2-S23D were
carried out following CK2α’ knockdown.
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Figure 34. Quantitation of repeat experiments from Figure 33. The co-IPs of E2 with
TopBP1 in the presence of Scr and CK2α’ siRNA were quantitated relative to the input
protein levels. The Scr co-IP levels were set as 1. * indicates a significant difference
between the two samples under the bracket, p-value < 0.05. Significance was determined
using a student’s t test and standard error was calculated from three independent
experiments.
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Figure 35. Quantitation of results from plasmid retention assay in U2OS cells followed
by siRNA knockdown of CK2α or CK2α’. We repeated our previously described plasmid
retention assay following the siRNA knockdown of CK2α or CK2α’. This is a summary of
three independent experiments carried out in duplicate.
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Figure 36. Western blot analysis to confirm siRNA knockdown of CK2α or CK2α’
throughout the plasmid retention assay. The indicated U2OS cells were treated with the
specified siRNAs and grown over the period indicated.
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Figure 37. E2 S23 is phosphorylated in vivo by CK2. siRNA knockdown of CK2α and/or
CK2α’, in indicated cell lines was carried out. Scr control siRNA was used in lanes 1 and
5. The top panels demonstrate the input proteins that were used in the immunoprecipitation
(IP) with pS23-Ab. Please note the CK2α blot is independent of the other inputs but the
same protein extracts were used. * is an antibody band.
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Figure 38. Western blot analysis to demonstrate the effect of CK2 inhibitor on E2TopBP1 interaction. Cells were treated with DMSO (lanes 1 and 2) or 10uM CX4945
(lanes 3 and 4) for 24 hours and then proteins were harvested. Top panels represent the
input levels of E2 and TopBP1, middle panels a TopBP1 co-IP and the bottom panel a
pS23-Ab co-IP. Please note a lane removed from these images but they are from the same
gel at the same exposure. * is an antibody band.
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E2 WT

E2 S23A

Figure 39. Representative immunofluorescence images of interphase and mitotic cells
stained with pS23-Ab. Left hand panels are antibody only, right hand panels are antibody
plus DAPI. There was no signal generated with secondary only antibody, and no signal
detected in pCDNA-Vec control when the primary antibody was included (not shown).
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3.2 Summary
The results in this section demonstrate that CK2 phosphorylation promotes E2 TopBP1 complex formation in vivo and in vitro via phosphorylation of serine 23. E2-WT
cannot interact with TopBP1 in vitro, while E2-S23D can. Incubation of E2-WT with CK2
promoted the interaction between E2 and TopBP1 recombinant proteins, and this was
reversed by treatment with lambda phosphatase. Further, by knocking down either α
component, or partial knockdown of both, it abolished detectable levels of E2 S23
phosphorylation in U2OS cells and partially disrupted the interaction between E2 and
TopBP1. CK2 has two catalytic domains, α and α’. So, knock down of only one CKα subunit would not completely eliminate CK2 function. The role of CK2 phosphorylation of
E2 S23 in U2OS cells was further confirmed using a CK2 inhibitor CX4945, which
disrupted the E2- TopBP1 interaction and further saw a loss of phosphorylation on the S23
residue, as determined by pS23-Ab co-immunoprecipitation experiment. Additionally, we
were able to determine that the pS23-Ab can recognize E2-WT, but not E2-S23A, in
mitotic and interphase cells. We also demonstrated that knockdown of CK2 α or α’ also
compromised the plasmid retention function of E2-WT, further signifying the role CK2
plays in mediating the E2-TopBP1 interaction. Given the many important functions of CK2
at different stages of HPV16 lifecycle, it is an ideal candidate to further investigate the
effect of CK2 inhibitors on cancers caused by HPV. We next wanted to expand our aim to
further study the role of CK2 phosphorylation of E2 S23 in a more physiological model
with the aid of human keratinocytes.
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3.3 E2 serine 23 phosphorylation by CK2 is needed for E2-TopBP1 complex
formation in human keratinocytes.
In a recently published paper from our lab, it was demonstrated that in N/Tert-1 (TERT
immortalized foreskin keratinocytes) cells, E2 can regulate transcription from the host
genome that is relevant to the viral lifecycle (231, 232). We used these cells to investigate
whether E2 retains plasmid retention function in keratinocytes, and whether CK2
phosphorylates S23.
3.3.1

E2-S23A mutation abolishes TopBP1 interaction and E2 plasmid retention

function in N/Tert-1 cells.
Using the N/Tert-1 cells, we generated stable pools of cell lines expressing E2-WT and
E2-S23A along with a pcDNA-Vec control. We confirmed the successful establishment of
our cell lines by western blot analysis of the cell lysates and Figure 40 A demonstrates the
expression of E2-WT and E2-S23A in the N/Tert-1 (lanes 2 and 3, Figure 40A). Coimmunoprecipitation with TopBP1 demonstrates that E2-S23A has a compromised
interaction with TopBP1 (compare lane 6 with lane 5, Figure 40B). The experiment was
repeated and results quantitated (Figure 40C). We additionally conducted a transient
transcription assay using these stable N/Tert-1 cell lines and demonstrated that E2-S23A
has similar transcriptional function as E2-WT in these N/Tert-1 cells (not shown).
Next, we carried out our plasmid retention assay in the N/Tert-1 E2-WT and the E2S23A cells and observed similar results to that in U2OS cells; the E2-S23A mutant has lost
the ability to retain the ptk6E2-luc plasmid when compared to E2-WT, and neither retain
pSV40-luc (Figure 41).
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3.3.2

CK2 phosphorylates E2 on serine 23 in vivo, and CK2 inhibitors disrupt the

E2-TopBP1 complex in N/Tert-1 cells.
To demonstrate if pS23-Ab recognizes E2-WT in N/Tert-1 cells, we carried out
immunoprecipitation with pS23-Ab (Figure 42A). We observed that pS23-Ab pulls down
E2-WT (lane 2, Figure 42A) which was lost with the addition of THE CK2 inhibitor,
CX4945 (compare lane 5 with lane 2, Figure 42A). In Figure 42B we also observed that
CX4945 disrupted the N/Tert-1 E2-WT interaction with TopBP1 (compare lane 6 with lane
3, Figure 42B). TopBP1 pulled-down E2-S23D and CX4945 treatments had no effect on
this interaction (compare lane 2 with lane 5, Figure 42B).
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A.

B.

C.

*

Figure 40. E2–TopBP1 interaction in N/Tert-1. (A) Western blot showing the expression
levels of indicated proteins in the stable N/Tert-1 E2 cells. (B) The protein extracts were
immunoprecipitated with HA (control) and TopBP1 antibody followed by western blotting
for TopBP1 and E2. (C) The experiment described for panel (B) was repeated and the
results were quantitated. * indicates a significant decrease in E2-S3A interaction with
TopBP1 when compared with E2-WT, p-value < 0.05. Significance was determined using
a student’s t test and standard error was calculated from three independent experiments.
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Figure 41. Quantitation of results from plasmid retention assay in N/Tert-1 cells. The
plasmid retention assay was carried out as described before in the stable N/Tert-1 E2-WT
and S23A cells. The experiment was repeated three times in duplicate. * indicates a
significant difference between the E2-WT and E2-S23A luciferase activity at the day 6 and
9 time points, p-value < 0.05.

88

A.

B.

Figure 42. Western blot analysis depicting E2 S23 is phosphorylated in vivo by CK2
in N/Tert-1 cell lines. (A) The extracts in the top panels (Input) were immunoprecipitated
with pS23-Ab or the extracts were immunoprecipitated with TopBP1 (B) following
treatment with the CX4945. DMSO treatment was used as control. * is an antibody band.
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3.3 Summary
In this section, we demonstrate that CK2 is responsible for the phosphorylation of
E2 serine 23 in N/Tert-1 cells and that this promotes interaction with TopBP1. We
successfully established our stable N/Tert-1 cells expressing E2-WT. E2-S23A and E2S23D and further demonstrated that the E2-S23A mutation also disrupted the E2-TopBP1
interaction in N/Tert-1 cells. We also determine that the E2-TopBP1 interaction in N/Tert1 cells is mediated by CK2 phosphorylation of serine 23. Our next aim was to explore the
role of E2 serine 23 in the HPV lifecycle.

90

3.4 E2 serine 23 and the HPV16 lifecycle
To date, the results demonstrate that the E2-TopBP1 interaction is promoted by CK2
phosphorylation of E2-S23, and that the E2-TopBP1 complex mediates E2 plasmid
retention function. Next, we investigated the role of the E2-TopBP1 interaction during the
viral lifecycle.
3.4.1

E2-TopBP1 interaction is required for the HPV16 lifecycle.

We introduced the S23A and S23D mutations into the HPV16 genome and generated
stable lines in N/Tert-1 cells, along with WT and pCDNA-Vec control lines. HPV16
transcriptionally reprograms the N/Tert-1 cell lines which support several markers of late
stages of the viral lifecycle (232-234). Early passage cells were organotypically rafted to
mimic the differentiation process. These were then formalin fixed and paraffin embedded
for lifecycle studies.
Figure 43A demonstrates a prominent difference in phenotypes between the N/Tert1+HPV16 mutants and WT. In Figure 43A (first panel), we observed that the H&E staining
demonstrated a more disorganized epithelium and transformed looking with significantly
higher koilocytes in N/Tert-1+HPV16-S23A and N/Tert-1+HPV16-S23D when compared
with N/Tert-1+HPV16-WT and that of N/Tert-1 pCDNA-Vec control rafts (in which no
koilocytes were detected). In HPV16 lesions, detection of koilocytes is potentially
diagnostic of HPV infection and disease progression (235). These koilocytes are squamous
cells with a large perinuclear vacuole and an acentric nucleus. Subsequently, we stained
for E2 and BrdU (to assess cellular proliferation) and detected higher E2 levels in the upper
layers of the epithelium in N/Tert-1+HPV16-WT (middle panels, Figure 43A). We
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observed a significant reduction in E2 staining in N/Tert-1+HPV16-S23A and N/Tert1+HPV16-S23D when compared with HPV16-WT cells. Increased BrdU labeling in
N/Tert-1+HPV16-WT was observed indicating enhanced basal cell proliferation as
described previously (232, 236) and this increase was not seen with the mutant genomes.
During the viral lifecycle, amplification occurs in the upper layers of the epithelium.
We made use of FISH, to detect the amplified HPV16 DNA in these cells. There was a
significant decrease in cells with amplified HPV16 DNA in the two mutant genomes when
compared with the wild type cells (panel three, Figure 43A). We predict that this reduced
amplification in mutant cells might be due to failure of stabilization of E2 and TopBP1
proteins during the viral genome amplification, which occurs in cells in G2/M phase during
the viral lifecycle (also demonstrated by cell synchronization experiment in Figure 16).
Previously, it was demonstrated that N/Tert-1+HPV16 cells have episomal HPV16
genomes and support late stages of the HPV16 lifecycle (237). We extended our study to
investigate whether E2 S23 is phosphorylated during the HPV16 lifecycle. For this
purpose, we stained N/Tert-1 and N/Tert-1+HPV16 organotypic raft cultures with the
pS23-Ab. We demonstrated that E2 is phosphorylated on serine 23 in the N/Tert-1+HPV16
cells (panel three, Figure 44) when compared to the isogenic control line, N/Tert-1 cells
where no positive signal was seen after pS23-Ab staining (panel one, Figure 44). In N/Tert1+HPV16, p-S23-Ab staining was detected throughout the epithelial layer and is mainly
nuclear in most of the cells. The staining outside of nuclei might be due to nuclear
breakdown in the upper layers of the differentiated epithelium. We additionally stained
W12e rafted cells that can support late stages of the viral lifecycle. W12 are cervical lesion
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cells and W12e are a clone that expresses E2 as it retains episomal HPV16. We also see a
robust positive signal in W12e rafted cells after staining with p-S23-Ab.
3.4.2

S23A mutation in the HPV16 genome resulted in delayed immortalization of

human foreskin keratinocytes and higher episomal viral genome copy number.
We next set out to investigate the role of E2-TopBP1 interaction during HPV
immortalization. We transfected HPV16 genomes containing the E2 S23A and S23D
mutations along with the wild type genome (HPV16-WT, HPV16-S23A, HPV16-S23D)
into three independent human foreskin keratinocyte (HFK) primary cell cultures to
generate immortalized cell lines. Initially, we successfully generated HPV16-WT and
HPV16-S23D immortalized cell lines in two out of three donors but failed to immortalize
any donor HFK cells by the HPV16-S23A variant (upon selection, HFK + HPV16-S23A
cells failed to maintain cell growth). To maximize our chances of obtaining immortalized
cell lines, we included feeder cells during transfection and selection. With this protocol,
we observed a diminished initial immortalization, with slow growing colonies with
HFK+HPV16-S23A as demonstrated by crystal violet staining (middle panel, Figure 45A).
Crystal violet staining following immortalization was conducted in duplicates for all three
lines, the result of which is summarized in Figure 45B. We observe a reduction in colony
formation with HPV16-S23A when compared with HPV16-WT and HPV16-S23D.
Following the initial lag, HFK+HPV16-S23A cells eventually grew out and its growth rate
was similar to HFK+HPV16-WT and HFK+HPV16-S23D (Figure 46).
Following this, the presence of the viral genome in these immortalized HFK cell lines
was investigated using Southern blot analysis (Figure 47) (238). SphI cuts the HPV16
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genome once and when the DNA from all HFK HPV16 lines was digested with SphI, it
generated an 8 kbp signal (top panel, Figure 47A). DNA from N/Tert-1 cells was used as
control and generated no signal (lane 3). In HFK+HPV16-S23D-3, we observe an
additional band of around 10kbp (lane 12 of top panel, Figure 47A). A HindIII digestion
(bottom panel, Figure 47A) which does not cut the HPV16 genome, generated open circular
DNA in all samples, as detected by the presence of slowly migrating species. In all HPV16S23A samples from all three donors, we observed significantly faster migrating bands
when compared with WT and S23D genomes containing cells (compare lanes 7-9 with the
other lanes). We detected more DNA present in the HFK lines containing the S23A variant
when compared with the WT, following SphI digestion (compare lanes 7-9 with 4-6).
Figure 47B depicts the quantitation of the signals generated in the HPV16 lines relative to
the 50 copy number (lane 2) in the SphI digest. In S23A samples, we see a statistically
significant increase in HPV16 genome copy number when compared to WT.
To determine whether E2 S23 mutation alters the episomal/integrated status of the
HPV16 genomes, we made use of a recent technique which utilizes exonuclease resistant
DNA as a measure of episomal status (221, 239, 240). This assay determines the resistance
of HPV16 genomes to exonuclease V (ExoV), which degrades linear but not circular DNA.
GAPDH was used as our linear standard and designated the dCt between samples plus and
minus ExoV as 100% degradation. We then took the dCt for a mitochondrial marker (a
circular genome) and E2 and E6 and determined the percent of degradation by comparing
the dCt difference with that of GAPDH. The assay was conducted using DNA from three
independent cell lines generated and results are summarized in Figure 48. The circular
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mitochondrial DNA is around 90% resistant in all samples. E2 and E6 are between
approximately 50 and 80% resistant. Table in Figure 48B summarizes the results from
these assays. Interestingly, HFK+HPV16-S23D-C is predominantly integrated, and the
additional band on the Southern blot (Figure 47A, lane 12) may be related to this. From
this experiment, with regards the episomal status of the viral genomes, we observe no
significant difference between HFK+HPV16-WT and HFK+HPV16-S23A/S23D. Hence,
the introduction of these mutations does not promote integration of the viral genome into
that of the host.
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N/Tert-1

+HPV16 WT

+HPV16 S23A

+HPV16 S23D

Koilocytes (a)

0

0.49+/-0.04

1.8+/-0.3*

1.7+/-0.2*

BrdU (b)

25.2+/-0.7

43.8+/-1.5^

20.5+/-0.5

24.6+/-0.6

E2 (c)

0

3.7+/-0.24

1.6+/-0.1*

1.5+/-0.2*

(a)
(b)
(c)
(d)
(e)

FISH (d)
0
10.2+/-0.5
3.1+/-0.2*
1.1+/-0.1*
Percent of cells that are koilocytes, relative to the number of DAPI cells
Percent of basal cells that are BrdU positive, relative to DAPI
Percent of cells positive for E2 staining, relative to DAPI
Percent of FISH positive cells, relative to DAPI
*significantly lower than wild HPV16WT; ^significantly higher than other lines

Figure 43. E2-TopBP1 mutation disrupts the HPV16 lifecycle. (A) N/Tert-1 cells
containing the E2-WT and E2-ToPBP1 mutations were rafted, formalin fixed, paraffin
embedded and sectioned for lifecycle studies. Left panels are H&E staining (koilocytes are
indicated by white arrow). E2 staining (in red) and BrdU incorporation (in green) were
carried out (middle panels). HPV16 DNA amplification was determined by FISH (in red,
right panels). (B) Quantitation of images in (A). The quantitation was carried out using
artificial intelligence via a Vectra Polaris as previously described (232-234). These results
are the work of Dr. Claire James.
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Figure 44. Detection of E2 S23 phosphorylation in HPV16 lifecycle models. The
indicated cell lines were organotypically rafted, formalin fixed and paraffin embedded then
sectioned. pS23-Ab (third panel) was carried out in N/Tert-1, N/Tert-1+HPV16 and W12e.
Pan-E2 staining served as the control. Lane 2 and 4 depicts merge of pan-E2 and pS23-E2
staining, respectively with DAPI staining. These results are the work of Dr. Claire
James.
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Figure 45. HPV16 S23A has diminished immortalization properties. (A) Primary
human foreskin keratinocytes (HFK) were transfected with the indicated HPV16 genomes
and cell colonies formed 2 weeks after transfection and selection with G418. Three
independent HFK donors were used. (B) Quantitation of the result shown in (A). * indicates
a significant reduction in colony size for E2-S23A, p-value < 0.05. These results are the
work of Dr. Claire James.
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Figure 46. The growth rates of the indicated cell lines following immortalization. A
growth curve was carried out over 15 days and the accumulated number of cells is plotted
on a log graph. Cell numbers were not statistically significant at any point.
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Figure 47. Southern blot analysis to determine the status of the HPV16 genomes in
the immortalized cells. (A) DNA extracted from the indicated cell lines were probed with
the HPV16 genome in Southern blots. Samples were digested with the HPV16 genome
single cutter Sph1 (top panel). Hind III does not cut the HPV16 genome (bottom panel).
(B) The bands in the top panel of A (Sph1 cut) were quantitated and are summarized here.
* indicates a significant increase in HPV16-S23A genome copy number, p-value < 0.05.
These results are the work of Dr. Claire James.

100

120
100
80
60
40
20
0
WT

A.

Percent TV exonuclease
resistant

E

B.

120

Mito

E2

E6

100
80

60
40
20
0

WT

S23A

S23D

HFK

Figure 48. Quantitation of result from the TV exonuclease assay. (A)To investigate the
episomal status of the HPV16 genomes in all cell lines we used the TV exonuclease assay.
Table in (B) details the result seen above. See section 3.4.2 for explanation. These results
are the work of Raymonde Otoa.
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3.4 Summary
In this section, we investigated the role of the E2-TopBP1 interaction during the viral
lifecycle. We introduced the S23A and S23D mutations into the HPV16 genome. Wild type
(WT) and mutant genomes were then transfected into N/Tert-1 cells to form stable cell
lines, which were rafted. Introduction of mutations resulted in more dysplasia with
increased koilocytes, decreased E2 stabilization and decreased viral genome amplification
during the viral lifecycle. We further demonstrated that E2 is phosphorylated on S23 during
the HPV16 lifecycle.
Additionally, when HPV16-S23A was introduced into HFK, it demonstrated delayed
ability to immortalize these cells. Moreover, the resultant immortalized cell lines that
eventually grow out from the HPV16-S23A transfected cells revealed increased episomal
viral genomes when compared with HPV16-WT. By using the recently developed TV
exonuclease assay, we have shown that the introduction of these mutations does not
promote integration of the viral genome into that of the host. This is further discussed in
chapter 4.
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CHAPTER 4
Discussion
HPV16 E2 protein is a multi-functional protein which has many vital roles during the
viral lifecycle. There is a gap in our understanding of host partner proteins and their roles
in E2 functions. In this study, we demonstrate that CK2 phosphorylation of E2 serine 23
leads to a complex formation with TopBP1, both in vitro and in vivo.
Serine 23 is conserved in all alpha-type HPV, which also includes high-risk HPVs,
without any known function (Figure 11). Further, the negative aspartic and glutamic acid
residues at -1 and -3 respectively, could indicate a potential CK2 target residue (241). In
vivo, mutation of S23 to alanine disrupts the co-immunoprecipitation of E2 with TopBP1,
while an aspartic acid mutation (which mimics the negative charge of phosphorylation)
retains interaction similar to E2-WT (Figure 13B). To demonstrate phosphorylation of S23
in vivo, we generated a phospho-specific antibody (pS23-Ab) which recognizes E2-WT,
including during mitosis, but not E2-S23A (Figure 39). CK2 exists as a tetramer composed
of two catalytic α-subunits (α, α′) and two β regulatory subunits (241).When either α
component is knocked down, or by partial knockdown of both components, we completely
eliminate detectable levels of E2 S23 phosphorylation in U2OS cells (Figure 37) and
further observe that knockdown partially disrupted the interaction between E2 and TopBP1
(Figure 38). The reason for this complete loss of phosphorylation, and only a partial loss
of interaction, could be due to the failure to detect residual E2 phosphorylation following
knockdown of the CK2 components. Unfortunately, pS23-Ab did not work in the western
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blots, it is possible the antibody only recognizes native E2 and not the denatured versions
needed for western blotting.
The loss of detectable phosphorylation on S23 residue with addition of the CK2
inhibitor CX4945 as shown by pS23-Ab immunoprecipitation in U2OS cells (Figure 37),
further confirms the role of CK2 in the phosphorylation of S23. We also see a disruption
of E2-TopBP1 interaction following the CK2 inhibitor CX4945 treatment (Figure 38). We
next expanded our studies in a more physiologically relevant model with the use of N/Tert1 cells, to demonstrate that S23 is critical for the E2-TopBP1 interaction (Figure 40) and
to further validate that that CX4945 abolishes detectable phosphorylation of E2 on S23
residue and blocks the E2-TopBP1 interaction in N/Tert-1 cells (Figure 42). We also
observed detectable E2 S23 phosphorylation during the HPV16 lifecycle in N/Tert-1 cells
(Figure 44). Our results additionally illustrate that CK2 phosphorylation of S23 mediates
the E2-TopBP1 interaction in vivo, we also demonstrated that CK2 controls this interaction
in vitro. E2-WT cannot interact with TopBP1 in vitro, but E2-S23D can (Figure 28).
Incubation of E2-WT with CK2 enzyme promotes the interaction between E2 and TopBP1
recombinant proteins (Figure 29), and this can be reversed by treatment with lambda
phosphatase (Figure 30). As E2 has been shown to interact with CK2 components (226),
this loss of interaction after the lambda phosphatase treatment demonstrates that the
enzymatic function of CK2 is required to promote the E2-TopBP1 interaction via
phosphorylation and that CK2 does not act as a “bridge” to bring the two proteins together.
We were not successful to express and purify recombinant E2-S23A to use as a control in
our in vitro studies. Nevertheless, the combination of in vivo and in vitro results
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demonstrates that CK2 phosphorylation of E2 S23 is crucial for E2-TopBP1 complex
formation.
The significance of investigating the role of CK2 in mediating HPV16 E2 function is
that CK2 has been implicated in several aspects of papillomavirus functions. CK2
phosphorylates BPV1 E2 on the 301 residue and this further regulates E2 protein stability
(242). This is not the case with HPV16 E2 as this residue is not conserved on HPV16 E2,
which is also shown in this study by the relatively equivalent expression levels of E2-WT
and E2-S23A in both U2OS and N/Tert-1 cells. CK2 can also regulate the DNA binding
of BPV and HPV E1 proteins and can control their DNA replication functions (243). CK2
phosphorylates and regulates HPV18 E1 function and is important in the lifecycle of
HPV18 and 11 (222, 244). CK2α was the critical component involved in regulating E1,
CK2α’ was not involved. CK2 phosphorylation of BRD4 is important for mediating
HPV16 E2 transcription and replication function, and studies from the Morgan lab along
with other groups have also demonstrated that a direct interaction between E2 and BRD4
is required for E2 transcription function (245-247). As well as regulating E1-E2 functions,
CK2 can also regulate the function of E7 proteins. Phosphorylation of a CK2 consensus
sequence on E7 is important for E7 degradation of p130 and the promotion of S-phase in
differentiated keratinocytes (248), and a HPV18 E7 CK2 target residue is required for
maintaining the transformed phenotype of cervical cancer cells (249). Overall, this critical
role of CK2 during multiple stages of viral lifecycle reiterates the need to investigate the
anti-viral and therapeutic effects of CK2 inhibition on HPV infection. The outcome from
this study is a step towards enhancing our understanding of the E2-TopBP1 interaction
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mediated by CK2 phosphorylation and to expand its importance and relevance into other
HR-HPV types.
E2 has three major functions in the viral lifecycle. From our transient assay results we
demonstrate the E2-S23A replication and transcription function is similar to E2-WT
(Figure 14). E2 also has an important third role, to mediate viral genome segregation into
daughter cells by actively associating with viral and human DNA simultaneously during
mitosis (250). E2 can bind to mitotic chromatin, and previously it was demonstrated that
E2 and TopBP1 co-localize on mitotic chromatin (187). We thus were intrigued to
investigate the interaction of E2-WT and E2-S23A with mitotic chromatin (Figure 15). E2WT showed robust staining on mitotic chromatin, and in addition it recruited TopBP1 onto
the mitotic chromatin. In control cells with no E2, TopBP1 does not “coat” the mitotic
chromatin as it does with E2-WT. Therefore, like BPV1 E2 and BRD4, E2 alters TopBP1
interaction with mitotic chromatin (251). Although we see that E2-S23A could retain some
mitotic E2 staining and could also recruit TopBP1, we observed a reduced E2 staining on
mitotic chromatin in our E2-S23A mutant when compared to E2-WT and this result was
reproducible. Cell cycle analysis demonstrates that E2-WT levels are increased during
mitosis, while E2-S23A levels are not, supporting our immunofluorescence results.
Furthermore, in this study we observed that E2-WT increases the levels of TopBP1 during
mitosis while E2-S23A cannot. Therefore, E2-WT and E2-S23A have distinct phenotypes
during mitosis. We are currently investigating whether E2 is stabilized during mitosis.
Subsequently, we investigated whether this difference could contribute to the ability of E2
to retain plasmids in the U2OS cells. Our results in Figure 21 demonstrates that E2-WT
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retains the plasmid with E2 binding site, over an extended period, while E2-S23A could
not. A non-E2 binding site plasmid could not be retained by either E2 protein. siRNA
knockdown of TopBP1 abrogated the ability of E2-WT to retain the E2 binding site
plasmid in this assay. Knockdown of CK2 α or α’ also compromised the plasmid retention
function of E2-WT, further demonstrating the critical role CK2 plays in mediating the E2TopBP1 interaction. These results demonstrate that an interaction between E2 and TopBP1
is critical for the plasmid retention function of E2-WT. The observation that E2-S23A
retains interaction with mitotic chromatin was interesting as previous work has
demonstrated that interaction with mitotic chromatin alone is not enough to mediate
plasmid retention function by E2, two properties seem to be required: chromatin attachment
and transactivation functions must be in sync for proper plasmid segregation (179). We
propose that there is an additional factor that could mediate the interaction of HPV16 E2S23A with mitotic chromatin and this is under active investigation, with our focus on
BRD4.
To further study the effect of E2-S23A mutation on the viral lifecycle, we introduced
S23A and S23D mutations into the HPV16 genome and used this to prepare N/Tert-1+
HPV16 cells lines. In a previous study from the Morgan lab, it was demonstrated that in
N/Tert-1 cells with the entire HPV16 genome (N/Tert-1+HPV16), the viral genome is
episomal and is amplified in the upper layers of organotypic raft cultures (232). From our
rafting study results we observe that morphology of the N/Tert-1+HPV16-S23A and
HPV16-S23D cells was disorganized and more transformed looking, when compared with
the wild type genome (Figure 43), and there were also occasional sections of thickened
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epithelium. There was an increase in FISH signal with both mutant genomes, and more
detectable replication towards the basal layers (Figure 43). N/Tert-1+HPV16 only
demonstrated a FISH signal in the upper layers of the epithelium, as expected. We then
stained the rafted N/Tert-1+HPV16 and vec control, along with W12e cells which were
isolated from cervical lesion and are a clone that retains episomal HPV16, and therefore
E2 expression. From Figure 44 it is evident that E2 is phosphorylated on S23 during the
HPV16 lifecycle.
We further saw E2-S23A genomes lagged in their ability to immortalize human
foreskin keratinocytes (HFK) (Figure 45). Also, the resultant immortalized cell lines that
ultimately grow out from the HPV16-S23A transfected cells have increased episomal viral
genomes when compared with HPV16-WT (Figure 47). The results from the recently
developed TV exonuclease assay also support this (Figure 48). One explanation to this is
that possibly, at the early stages of establishing immortalization, the viral genome
segregation function of E2 is critical to spread the viral genome to daughter cells, and with
the S23A mutant genomes this is not occurring. This might explain the delay in initial
immortalization in S23A mutant. This process may also explain the increase in viral
genome copy number with the S23A mutant as the viral genomes may be mis-segregated
into a smaller number of cells, resulting in the ultimate growth of immortalized HFK that
have increased viral genomes. Additionally, in the HFK+HPV16-S23A immortalized cell
lines, there is a significant increase in faster mobility genomes when compared with
HFK+HPV16-WT on Southern blots where the viral genomes have not been cut (Figure
47A). During mitosis, TopBP1 is required for decatenation of the host genome to promote
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the correct segregation of the host chromosomes into daughter nuclei (252, 253). Probably,
the E2-TopBP1 interaction plays a similar role for the circular viral genome during mitosis,
ensuring that individual viral genomes reside in the daughter nuclei and are therefore
substrates for replication. Therefore, the faster migrating genomes observed in Southern
blot analysis of HFK+HPV16-S23A cells could be those that remain catenated. This defect
in decatenation could also delay the growth of immortalized HFK.
Moreover, in monolayer cell culture, the HFK lines grew equally well (Figure 46)
which would suggest that the viral genomes are not being lost in HFK+HPV16-S23A
during this period, as loss of viral genomes would result in a reduction in proliferation. As
the monolayer cell culture model does not support and depict the actual different viral
lifecycle stages, perhaps during the culture of the HFK in monolayer, the E2-TopBP1
episome retention mechanism is not required to maintain viral genome copy numbers. This
needs to be further explored to determine the contribution of the E2-TopBP1 interaction to
multiple stages of the viral lifecycle.
Previously, it was demonstrated that E2 regulates host gene transcription and that this
property is essential for the viral lifecycle (231, 254). TopBP1 regulates transcription of
E2F and p53 and therefore interaction with E2 could disrupt this process (255, 256).
Studies have also demonstrated that TopBP1 regulates host gene transcription during
keratinocyte differentiation (257). Although we cannot detect any difference in the
replication functions of E2-WT and E2-S23A in our transient replication assays, it is
possible that the S23A mutation could compromise the replication function of E2 during
immortalization. We are presently investigating to identify what aspects of the lifecycle is
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affected by the introduction of the S23A mutation into the HPV16 genome which resulted
in an aberrant HPV16 lifecycle in human keratinocytes seen in our results.
Overall, in this study, we have demonstrated that CK2 phosphorylation of E2 on serine
23 promotes interaction with TopBP1, and that this is crucial during the viral lifecycle. The
difference in phenotypes observed in our results is suggestive that disrupting this
interaction further abrogates the plasmid retention function of E2. As CK2 is essential in
different stages of HPV16 lifecycle, we propose that CK2 could be a potential therapeutic
target for treating HPV16 related HNSCC.
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CHAPTER 5
Conclusion and future work
The prevalence of HPV positive HNSCC are on the rise, especially among men, despite
the availability of vaccine against HPV16, 18 and also HPV 6 and 11. There is an urgent
need to develop novel antiviral therapeutics targeting the HR-HPVs as the vaccine is only
prophylactic and cannot treat pre-existing HPV infections and related conditions. Only
with a deeper understanding of the HPV lifecycle, it is possible to develop a successful
strategy to treat HPV related cancers.
In this study, for the first time, we have identified the chromatin receptor for HPV16
E2, demonstrating that the E2-TopBP1 interaction is promoted by CK2 phosphorylation
and can mediate plasmid segregation function and regulate the viral lifecycle (Figure 49).
The outcomes of this study will enhance our understanding of HPV lifecycles which is are
major human pathogens responsible for 5% of all cancers.

Figure 49. A schematic model depicting a summary of the results deduced from this
study.
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Targeting the E2-TopBP1 interaction can be promising for the reasons listed below:
1. The interaction between TopBP1 is confirmed in BPV1 E2, which is suggestive
that the interaction might be conserved across all PV types. TopBP1 is the mitotic
chromatin receptor for HPV16 E2, it further aids E2 to regulate the host genome and is
essential for optimal viral DNA replication mediated by E2, making this an ideal target for
viral therapy development.
2. CK2 has been implicated with regards to several PV functions. Furthermore, in this
study, we demonstrate that CK2 phosphorylates E2 on serine 23 in vivo, and that CK2
inhibitors disrupt the E2-TopBP1 complex. Our results suggest that CK2 inhibitors such as
CX4945, a drug in clinical trials for several human cancers (230), may be useful to disrupt
the E2-TopBP1 dependent HPV16 lifecycle and potentially kill HPV16 positive cancers
(Figure 50).

Figure 50. A schematic depicting a potential impact E2-TopBP1 interaction
could have with regards to a direct therapeutic relevance.
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Future directions
The bromo-domain protein, Brd4 is the host mitotic receptor for BPV1 E2 (258-261).
Further, HPV16 E2 transcription and replication function is mediated by CK2
phosphorylation of Brd4 (123, 262). Previously, it has been established that Brd4 to be an
essential transcriptional co-activator for all E2 proteins (245-247) and Brd4 is a ubiquitous
protein found in all proliferating cells (155). In our immunofluorescence results (Figure
15), we observed that E2-S23A could retain interaction with mitotic chromatin despite not
being able to complex with TopBP1. This prompted us to explore if this interaction of E2S23A with mitotic chromatin is mediated by an additional factor. Given its various
important roles, in our future studies, we aim at exploring if Brd4 could be a part of the
complex that could potentially mediate the E2-S23 interaction with host mitotic chromatin.
Our preliminary data seems to support this.
To understand the role of Brd4 in the complex, we made a stable E2 cell line in U2OS
carrying the mutant E2-R37A (arginine to alanine at position 37) which was previously
characterized (158, 176, 263). We then harvested the lysate and repeated the
immunoprecipitation with TopBP1 antibody as before. From Figure 52, we observe that
E2-R37A mutant interacts with ToPBP1 similarly to E2-WT and E2-S23D phospho
mutant, and unlike E2-S23A, where this interaction is lost. Furthermore, IP with Brd4 pulls
down both E2-S23A and E2-WT (Figure 53). Next, when we synchronized the U2OS cells
using double thymidine block, we observed that there was a significant increase in E2 and
TopBP1 levels 8 hours following release in the E2-WT cells, but an increase of neither E2
nor TopBP1 in E2-R37A or Vec control cells (Figure 54). This solidified our theory that
113

E2-S23 is the site of interaction between E2 and TopBP1 and not mediated by E2-R37. We
are currently expanding the study with the use of a E2-S23A+R37A double mutant, to
further dissect the role of Brd4 in the complex. In our future studies, we aim to make use
of the E2-R37A and the E2-S23A+R37A double mutant to study the effect of these Brd4
mutation on the mitotic interaction of E2. We further want to study the effect this double
mutation has on the transcription function of E2 and its role in the viral lifecycle.
We propose a model that during mitosis, TopBP1 might function as a chaperon that
interacts with E2 one side and this interaction leads to stabilization of both proteins on the
mitotic chromatin. Next, with its other side, TopBP1 may bind to one of Brd4’s
bromodomains. Brd4 would then interact with both the host chromatin and transcription
factors, potentially recruiting the E2-TopBP1 complex to open sites of chromatin and the
promoters of host genes for their regulation. This could further play a role in mediating
genome segregation as well as DNA replication and transcription functions of the E2
protein, needed for the virus to carry its lifecycle (Figure 51).
Additionally, future studies will also focus on more in-depth lifecycle studies to
determine the contribution of the E2-TopBP1 interaction to multiple stages of the viral
lifecycle.
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Figure 51. A proposed model and roles of a potential TopBP1-Brd4- E2 complex.

Furthermore, we aim to identify the TopBP1 domain that E2 interacts with to form the
complex. Previous studies have identified several TopBP1 domains that interact with
phosphorylated peptides (228). The region around E2 S23 does not correspond to a
consensus sequence for interacting with any of these TopBP1 domains and in fact, an E2
pS23 peptide does not interact with any of these domains (Figure 55). This indicates that
E2 interacts with a yet to be identified domain of TopBP1. Our aim is to identify this
domain, as this will help us to determine whether E2 has evolved a unique way to interact
with TopBP1 that does not disrupt the ability of TopBP1 to interact with host proteins
involved in the DNA damage response, a process essential for HPV lifecycles (205).
Identifying this TopBP1 functional domains involved in the HPV16 genome segregation,
could serve as potential therapeutic target.
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Figure 52. Western blot analysis to demonstrate E2-TopBP1 interaction in E2-R37A
mutant. (A) Western blot showing the expression levels of indicated proteins in stable
U2OS E2 cells. (B) The protein extracts were immunoprecipitated with HA (control) or
TopBP1 antibodies followed by western blotting for TopBP1 and E2.
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Figure 53. Western blot analysis to demonstrate E2-Brd4 interaction (A) Western blot
showing the expression levels of indicated proteins in stable U2OS E2 cells. (B) The
protein extracts were immunoprecipitated with HA (control) or Brd4 antibodies followed
by western blotting for TopBP1, Brd4 and E2.
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Figure 54. Cell synchronization and western blot analysis on U2OS E2 cell lines. U2OS
lines as indicated, were double thymidine blocked to coordinate them in G1. The cells were
then released for the time points shown, and protein extracts harvested and western blots
carried out.
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Figure 55. The E2 pS23 peptide does not interact with well characterized phosphopeptide binding domains of TopBP1. Fluorescent polarization assays were carried out
with the indicated peptides and TopBP1 BRCT containing domains. The control peptides
are known interactors of the indicated TopBP1 domains, see (228) for details.
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